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Initial studies demonstrated that Inhibitor of DNA binding/differentiation protein 
4 (Id4) acts as a tumor suppressor in prostate cancer (PCa). To further confirm and 
investigate the mechanism by which ID4 acts as a tumor suppressor, herein we 
concentrated on two different approaches. In the first approach we investigated ID4 role 
as a tumor suppressor by regulating AKT/PI3K pathway. In the second approach, we 
examined the role ofld4 in blocking the tumorogenic properties of metastatic PC3 cells. 
Phosphoinositide 3-kinase/Protein kinase B (PB/AKT) pathway regulates multiple 
biological processes leading to cell survival, proliferation and growth in cancerous cells. 
We performed immunohistochemistry (IHC) to determine AKT, pAKT and PTEN 
protein expression in Id4 knockout mouse prostates and PCa cell lines. IHC on Id4 
knockout mouse prostates demonstrated a significant decrease in PTEN expression as 
compared to normal mouse prostates. Consistent with decrease PTEN, the expression of 
pAKT expression increased. Similar pattern was observed in PCa cell lines: DU145 cells 
lacking Id4 had low PTEN as compared to ld4 over-expressing DU I 45 cells. In addition, 
Chromatin immunoprecipitation (Ch!P) analysis also demonstrated an increase in the 
binding of acetylated p53 on PTEN promoter in the presence of Id4. 
The second approach demonstrated the tumor suppressor function of Id4 in highly 
tumorogenic and metastatic PC3 cell line. Interestingly, this study demonstrated that 
overexpression of Id4 in PC3 cells results in decreased tumorogenecity in part through 
increased expression of Androgen receptor (AR) and its target genes Cyclin dependent 
inhibitor I (p21) and FK506-binding protein 51 (FKBPS l ). Apoptosis, migration and cell 
proliferation decreased in the Id4 overexpressed PC3 cells. Mice injected with PC3 + Id4 
cells showed decreased tumor size and volume. IHC studies on tumor xenografts 
demonstrated increased levels of AR, Ki67, and p21 in Id4 overexpressed xenograft. 
Collectively, our data indicate that 1D4 acts as tumor suppressor by regulating the levels 
of PTEN by prompting the binding ofacetylated p53 onto PTEN promoter which 
eventually results in inhibiting P13K/AKT pathway. Furthermore, Id4 not only increases 




With God everything is possible. First, I would like to thank God for giving me 
the wisdom to put you in the center of things I do. I would like to thank my mentor and 
doctoral advisor, Dr. Jaideep Chaudhary, for his kindness, dedication, invaluable support 
and advice during my matriculation at Clark Atlanta University. I would also like to 
thank my committee members: Ors. Cimona Hinton, Valerie Marah, Joann Powell, and 
Shailesh Singh, for their accolades, affirmations, and criticisms required along this 
journey. I would like to thank all the former/current members of Dr. Chaudhary's lab and 
graduate students in Department of Biological Sciences. Finally, I would like to thank my 
beloved mother and father for their unconditional love, sacrifice and support. I would like 
to thank my wife, brother, sister and my family for their endless love, support and great 
encouragement at all times throughout my studies. 1 would also like to thank the 
financial, academic and technical support of the Clark Atlanta University, the chair and 
the staff of the Department of Biological Sciences and Center for Cancer Research and 
Therapeutic Development. This work was funded by NIH/NCRR/RCMI grant 
#Gl2RR03062 and NIH grant #R0ICA128914 and the Department of Biological 
Sciences for supporting my doctoral thesis. 
111 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ............................................................................................... iii 
LIST O FIGURES ............................................................................................................ viii 
LIST OF TABLES ............................................................................................................... x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
CHAPTER 
PART I: ROLE OF ID4 IN PTEN/AKT PATHWAY 
I. INTRODUCTION ................................................................................................... 1 
II. LITERATURE REVIEW ........................................................................................ 5 
2.1 Cancer Epigenetics and Genetic Instability ................................................. 5 
2.2 Structure I Function of Prostate ................................................................... 6 
2.3 Molecular Biology and Histology of Prostate ............................................. 7 
2.4 PCa ............................................................................................................... 7 
2.5 PCa Incidence .............................................................................................. 8 
2.6 Risk Factors ................................................................................................ 8 
2. 7 Progression ................................................................................................... 9 
2.8 Treatment ................................................................................................... 10 
2. 9 Tumor Promoters in PC a ........................................................................... I 0 
2.10 Tumor Supressors in PCa ......................................................................... 11 
2.11 Tumor Supressor: PTEN .......................................................................... 12 
2.12 PTEN Structure ........................................................................................ 13 
2.13 PTEN Localisation (in the Nucleus) ........................................................ 14 
IV 
CHAPTER 
2.14 PTEN and Regulation of the PJ3K/AKT/mTOR Pathway-PCa .............. 15 
2.15 PJ3K/AKT/mTOR-lndependent Functions of PTEN .............................. 17 
2.16 Function of PTEN ................................................................................... 17 
2.17 Transcriptional Role ofPTEN ............................. .................................... 18 
2.18 Post-Transcriptional Role of PTEN ......................................................... 19 
2.19 Post-Translational Role of PTEN ............................................................ 19 
2.20 Helix Loop Helix (HLH) and Basic HLH (bHLH) Proteins ................... 20 
2.21 Inhibitor of Differentiation/Inhibitor of DNA Binding (ID) Proteins .... 20 
2.22 Inhibitor of DNA Binding 4 (ld4) Protein ............................................... 24 
2.23 Id4 Expression in Normal Prostate .......................................................... 27 
2.24 Id4 is Epigentically Silenced in Cancer ................................................... 28 
2.25 ID4 is Epigentically Silenced: Acetylation Study ................................... 29 
2.26 Id4 Acts as a Tumor Suppressor ............................................................. 30 
2.27 PTEN/AKT Pathway and Id4 .................................................................. 32 
2.28 Id4 Regulates PTEN/AKT Pathway ....................................................... 33 
III. MA TE RIALS AND METHODS ......................................................................... 3 7 
3.1 1D4 Overexpression and Silencing in PCa Cell Lines ............................... 37 
3.2 Reverse Transcriptase ................................................................................ 38 
3.3 Quantitative Real Time PCR (qRT-PCR) .................................................. 38 
3.4 Protein Extraction ...................................................................................... 39 
3.5 Western Blot Analysis ............................................................................... 39 
V 
CHAPTER 
3.6 Cell Proliferation Assay ............................................................................ .41 
3.7 Statistical Analysis (Proliferation) ............................................................ .41 
3.8 Apoptosis Assay ......................................................................................... 41 
3.9 Statistical Analysis (Apoptosis) ................................................................ .41 
3.10 AKT Kinase Assay ................................................................................. .42 
3.11 Migration Assay ...................................................................................... .42 
3.12 Tunel Assay ............................................................................................ .43 
3.13 Luciferase Reporter Gene Assay ............................................................. 43 
3.14 Immunohistochemistry (IHC) ................................................................. .44 
3.15 DNA Methylation Analysis .................................................................... .44 
3.16 Bisulfite Sequencing ............................................................................... .45 
3.17 siRNA Transient Transfections ............................................................... .45 
3.18 Chromatin lmmunoprecipitation (ChIP) Assay ...................................... .45 
3.19 Statistical Analysis (ChIP) ....................................................................... 46 
3.20 lmmuno-Cytochemistry ........................................................................... 46 
3.21 Site-Directed Mutagenesis ...................................................................... .47 
IV. RESULTS ............................................................................................................ .48 
4.1. ld4 Regulates PTEN Expression/Function .............................................. .48 
4.1.1. Methylation and Acetylation of PTEN Promoter .......................... .49 
4.1.2. Id4 and p53 Acetylation .................................................................. 50 
4. I .3. Binding of Acetyl p53 on PTEN Promoter ..................................... 5 I 
VI 
CHAPTER 
4.2. Role of PTEN-pAKT Axis in Regulating ld4 Phosphorylation ............... 52 
4.2.1. Kinase Assay: Id4 Regulates PTEN/AKT Axis .............................. 53 
4.2.2 Treatment with Pl3K Inhibitor Lead to Id4 Expression 
in DUl45 Cells ............................................................................... 54 
V. DISCUSSION AND CONCLUSION ............................................................... .56 
PART II: ID4 PROMOTES AR EXPRESSION AND BLOCKS 
TUMORIGENICITY OF PC3 PROST A TE CANCER CELLS 
VI. INTRODUCTION .............................................................................................. 59 
VII. LITERATURE REVIEW ................................................................................... 60 
7.1 AR in Prostate ............................................................................................ 60 
7.2 AR as Tumor Suppressor and Tumor Promoter ........................................ 61 
7.3 AR Regulated Transcriptional Factor: FKBP51 ........................................ 62 
7.4 ID4 and AR ................................................................................................ 63 
VIII. RES UL TS ........................................................................................................... 66 
8.1. Generation of!D4 Expressing PCa Cell Line ........................................... 66 
8.2. Effect of ID4 on Morphology, Cell Proliferation and Migration .............. 66 
8.3. ID4 Promotes AR Expression ................................................................... 68 
8.4. ID4 Results in Decreased Tumor Growth In Vivo ................................... 70 
IX. DISCUSSION AND CONCLUSION ................................................................ 72 
REFERENCES ................................................................................................................... 74 
Vil 
LIST OF FIGURES 
Figure 
I. Domain structure of HLH family ...................................................................... .4 
2. The adult prostate and surrounding structures ................................................... 6 
3. Regulation of PTEN transcription ................................................................... 13 
4. AKT pathway ................................................................................................... 16 
5. bHLH transcription factors .............................................................................. 22 
6. Oncomine database .......................................................................................... 27 
7. Expression ofld4 in normal prostate ............................................................... 27 
8. PCa tissue microarrays ..................................................................................... 28 
9. Id4 promoter methylation ................................................................................ 29 
I 0. Treatment with NaBr ....................................................................................... 30 
11. ld4 induces apoptosis in DU 145 cells ............................................................. .31 
12. Id4 promotes senescence in DU 145 cells ........................................................ 31 
13. IHC data on PTEN, AKT and phospho-AKT (p-AKT) .................................. .33 
14. PTEN mRNA data ........................................................................................... 34 
15. PTEN protein expression ................................................................................ .34 
16. Expression levels ofphospho AKT and AKT ................................................ .34 
17. ID protein sequences ........................................................................................ 35 
18. NetPhosK 1.0 Server ........................................................................................ 36 
Vlll 
Figure 
19. Predicted Id4 phosphorylation model ............................................................. .36 
20. PTEN promoter methylation and acetylation ................................................. .49 
21. IHC on Id4-/- with p53, Acetyl p53 and p2 l ................................................... 51 
22. Ch!P Assay: Increase in the binding of Acetylated p53
to PTEN Promoter. ........................................................................................... 52 
23. Kinase Assay .................................................................................................... 53 
24. Treatment with L Y294002 ............................................................................... 55 
25. Kinase Assay showing pAKT activity ............................................................. 55 
26. Id4 Phosphorylation ......................................................................................... 55 
2 7. Androgen receptor expression analysis ........................................................... 64 
28. Gene expression changes in DU145+ld4 cell lines ......................................... 65 
29. Stable overexpression of1D4 with pCMV-1D4 in PC3 cells ........................... 67 
30. 1D4 regulates migration ................................................................................... 68 
31. ID4 regulates expression of AR ....................................................................... 69 
32. Stable overexpression of 1D4 in PC3 cells suppresses tumor growth
in vivo .............................................................................................................. 71 
IX 
LIST OF TABLES 
Table 
I. ld4 Modulation in Cancer ....................................................................................... .3 
2. qRT-PCR and Ch!P Primers Used in the study ...................................................... 39 




















LIST OF ABBREV IA TIO NS 
Analysis of Variance 
Activating Protein 2 
Androgen Receptor 
Bovine Calf Serum 
Base Pair 
Benign Prostatic Hyperplasia 
Breast Cancer Resistance Proteins 
Bone Morphogenetic Protein 
Breast Cancer I 
Bovine Serum Albumin 
Centromere Binding Factor I 































Epidermal Growth Factor 
Early Growth Response 
Estrogen Receptor 
Extracellular Signal- Regulated 
Fetal Bovine Serum 
FK506-Binding Protein 
Helix Loop Helix 
Immunocytochemisty 
Inhibitor of DNA Binding 
Extracellular Signal-Regulated Kinases 
Enhancer of Zesta Homolog 2 
Tri Methylation of Histone 3 at Lysine 27 
Immunohistochemistry 
Mouse Double Minute 2 Homolog 
Matrix Metalloproteinase 
Messenger Ribonucleic Acid 
Methylation Specific-Polymerase Chain Reaction 
Nuclear Factor KappaB 
Phosphate Buffered Saline 
Polymerase Chain Reaction 
Phosphoinositide 3-Kinase 
Prostatic-Intraepithelial Neoplasia 








Prostate Specific Antigen 
Phosphatase and Tensin Homolog 
Polyvinylidene Difluoride 
Reverse Transcriptase 




ROLE OF 104 IN PTEN/AKT PATHWAY 
CHAPTER! 
INTRODUCTION 
The helix-loop-helix (HLH) family of transcription factors comprises >200 
members, which have been identified in organisms from yeast to man_ 1-2 The basic helix­
loop-helix (bHLH) family of transcription factors are key players in many developmental 
processes,3 such as differentiation of various cell types, such as in Band T-lymphocytes, 
muscle lineages, pancreatic B cells, neurons and osteoblasts.4·5 Most (bHLH) proteins
that form a large super family of transcription factors that regulate tissue-specific 
transcription,6 positively regulate sets of genes during cell fate determination and cell
differentiation. Members of this family have two highly conserved domains. The 
carboxyl terminal end ofbHLH contains the HLH domain involved in homo or hetero 
dimerization with other bHLH proteins that regulate transcription and the amino terminal 
end which contains the basic domain facilitates binding to DNA containing the canonical 
'E box' recognition sequence, CANNTG and 'N box' sequence, CACNAG 2 or Ets 
recognition sequence, GGAA/T present in the promoter regions of regulated proteins.4
Thus bHLH proteins form a large super family of transcription factors that regulate 
tissue-specific transcription.6 The bHLH hetero-homo dimer plays an important role in 
many physiological processes including cellular differentiation, apoptosis, cell cycle 
arrest and regulate critical developmental processes.7 A distinct subfamily ofHLH 
proteins, the Inhibitor of differentiation (ID) proteins, lack these basic DNA-binding 
I 
2 
region and instead function solely by dimerization with other transcriptional regulators, 
principally those of the bHLH type and such ID-bHLH heterodimers are unable to bind to 
DNA, and hence ID proteins act as dominant negative regulators ofbHLH proteins.8•9 Ids
are known to interact with other bHLH proteins such as E2A, E2-2, or HEB, and also 
with factors such as RB (retinoblastoma) family members that have a role in cell cycle.4
In highly proliferating cells, ID proteins are typically expressed while there 
expression levels decrease in differentiated cells. Ids are known to be positive regulators 
of cell growth and negative regulators of cell differentiation. 10 ID proteins play key roles 
in the regulation of lineage commitment, cell fate decisions, 11 and also have a role in cell 
signaling, DNA damage control, and apoptosis. They also act in the timing of 
differentiation during neurogenesis, lymphopoiesis and neovascularisation (angiogenesis) 
and are essential for embryogenesis and cell cycle progression. 11 ID proteins that consists 
of!D I, ID2, ID3 and ID4 are dominant negative transcriptional regulators of basic Helix 
Loop Helix (bHLH) transcription factors that lack the basic DNA binding domain but 
have intact HLH domain that is conserved in all ID proteins. 12 Out of four ID proteins, 
ID4 appears to act primarily as a tumor suppressor in most cancers as opposed to ID I, 
ID2 and ID4, which in most cases acts as tumor-promoters or supporting oncogenes. 13·14•
Previous studies from our lab, demonstrated that Id4 acts as a tumor suppressor in PCa 
via regulating not only various tumor suppressors and tumor promoters but also through 
various regulatory pathways such as PTEN/AKT, p53 and AR pathways. 15•20 Id4 has
been shown to act differently depending on the tumor type as shown in Table 1. 
Table 1: ld4 Modulation in Cancer 
Kind of Modulation 
Downregulated 
Down Regulated in Low 
Grade Cancer vs 
Hyperplasia Upregulated 




















Study between ld4 and PTEN expression suggests that there is some cross-talk 
between AKT pathway and ld4. In this study loss of Id4 in mouse prostates resulted in 
decreased expression of PTEN leading to increased pAKT expression levels. 18
Previous studies demonstrated, binding of p53 to PTEN promoter can enhance the 
regulation of PTEN and thus can mediate cell cycle arrest and apoptosis by promoting 
stabilization, acetylation and tetramerization ofp53.21•22 Id4 that regulates PTEN activity
and expression, and vice-versa pAKT expression levels, might play a role when PTEN 
inactivation increases the expression and activity levels of Mouse double minute 2 
(MDM2) a known p53 repressor by PBKJAKT dependent pathway.23 In the presence 
PTEN, p53 gets upregulated through translational mechanisms mediated by mTORCI.24
Previously we have shown that ld4 has a role in p53 pathway where ld4 restores p53 
transcriptional activity. 15 HLH domain is shown to be conserved in all ID proteins that is 
involved in DNA binding and transcriptional activity ofID proteins.25 Domain structure
3 
4 
of HLH protein family has HLH domain, and ld4 which belongs to HLH family lack the 
basic domain, which is shown in Figure 1. Serine residue at position 5 in ld2 is the one to 
get phosphorylated, that inturn makes Id2 to act as a tumor promoter and vice-versa.26 ld4 
which has the same HLH domain and serine 5, might also act in similar fashion as Id2 
when it gets phosphorylated. To study this, we investigated, whether the association 




Figure I. Domain structure of HLH family. A represents HLH domain that also contains basic amino 




2.1 Cancer Epigenetics and Genetic Instability 
Disruption of regulatory circuits which maintain cellular homeostasis leads to 
development of cancer. The hallmarks of cancer include, insensitivity to anti-growth 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, tissue 
invasion and metastasis.27 Genes can be inactivated as a result of deletions, mutations or 
epigenetic mechanisms and also can be deregulated by amplifications or chromosomal 
translocations.28
There is often more than one genetic aberration present in many cancers. Cancer 
cells acquire somatic mutations as part of normal development which differ from any 
germline mutations. Those mutations which give proliferative and/or survival responses 
to cells are acquired as part of an on-going process during development. These somatic 
mutations are categorised as 'drivers' or 'passengers'. 'Drivers' are defined as those 
mutations which give the cells a survival advantage. 'Passenger' mutations are those 
mutations which allow the ancestry of the cell to be mapped but are not beneficial for the 
cells survival.29 According to the classical mechanism, genomic instability (deletions or 
translocations) due to inactivating mutations in tumor suppressor genes or gain of 
function mutations in oncogenes resulting in uncontrolled growth is considered as a 
tumor initiating event. 
5 
More recently, loss of function (expression) through epigenetic changes due to 
altered pattern of DNA methylation and histone modification, is gaining significant 
attention as an additional pathway involved in cancer initiation and progression.30-32 
These epigenetic changes could predispose the inherited genome of subsequent 
generations to mutagenic/genotoxic alterations leading to the development of sporadic 
PCa.33 Thus, combined genetic and epigenetic changes are now considered as cancer
initiating events. 
2.2. Structure I Function of Prostate 
6 
The prostate gland which weighs approximately 40 grams, is a walnut sized gland 
in the male reproductive system just below the bladder that supplies fluid for the sperm 
during ejaculation.34 A newborn male's prostate is very small about the size of a grain of 
wheat. At the onset of puberty it begins to grow dramatically until around the age of 
twenty and fairly constant until the forties, then due to dihyrotestosterone (DHT) and 
estrogens the prostate begins to bulk up. It is divided into 2 lobes and contains smooth 
muscle cells capable of contracting to expel the prostatic fluid.35 The structure and the 




Figure 2. The adult prostate and surrounding structures. TI1e base of the prostate is located at the bladder 
neck. The urethra bisects the prostate. (B) Illustration showing, two examples of PCa: the top, which grew up next to 
the urethra causing its compression and to the bottom showing it comes out of urethra causing urinary problems. 
7 
2.3 Molecular Biology and Histology of PCa 
Anatomically prostate is composed of the central, transition, peripheral zones, and 
a region of the anterior fibromuscular stroma, which is the most anterior prostatic 
structure. Posterior to the stromal region are the paired central zones. Interior to the 
central zones are the transition zones which are located on either side of urethra. The 
transition zones represent the smallest zone in the normal prostate. And lastly the 
peripheral zone is the largest region of the normal adult prostate, which is located on the 
posterior side of the prostate. Benign prostatic hyperplasia (BPH), a nonmalignant 
overgrowth that is fairly common among aging men, occurs mainly in the transition zone, 
whereas prostate carcinoma arises primarily in the peripheral zone.36 
Histolgically, prostatic glands are composed of different cell types. The luminal 
epithelial cells which are androgen-dependent, produce prostatic secretions.36•37 Luminal 
epithelial cells are characterized by expression of androgen receptor and cytokeratins 8 
and 18. Basal cells that form a continuous layer between the luminal cells and basement 
membrane are most abundant cells with cytokeratins 4, 14 and p63 as markers.36 The 
third cell type is neuroendocrine cells which are androgen independent and are dispersed 
throughout the basal layer.38 Strama that surrounds the epithelial glands is composed of
smooth muscle fibers, fibroblastic, neuronal, vascular and lymphatic cell types, and can 
be identified using alpha-actin and vimentin as markers.39 
2.4 PCa 
PCa also known as adenocarcinoma develops mostly from gland cells that make 
prostate fluid which is added to the semen.40 Other types of cancers such as sarcomas,
small cell carcinomas and transitional cell carcinomas which are rare can also start in the 




PCa is the second leading cause of cancer deaths in men. 42 In the year 2013 there 
are an estimated 238,590 new cases of PCa and predicted deaths are almost 29,750 in the 
United States. Of all the cancer deaths, PCa deaths account for approximately 5.1 percent 
with 15.3 percent of men will be diagnosed with PCa at some point during their 
lifetime.43 African American men are twice more likely to have PCa incidence compared 
to that of Caucasians and Asian men and have nearly a two-fold higher mortality rate 
than Caucasian men.44 Most PCa related deaths are due to spread of malignant cells to 
tissues other than prostate, known as metastasis. 45
2.6 Risk Factors 
A risk factor separates patients without known disease into those at increased or 
decreased likelihood for disease and for men who develops aggressive cancer there is a 
great need for such factors. Risk factors can be classified as endogenous or exogenous. 
Endogenous risk factors for prostate include family history, hormones, race, aging and 
oxidative stress. Diet, environmental agents, occupation and other factors such as 
smoking, energy intake, sexual activity, marital status, vasectomy, social factors, physical 
activity and anthropometry come under exogenous risk factors,46 for PCa. Any study of 
risk of PCa depends on five unique characteristics that contribute to its unpredictable and 
paradoxical clinical behavior. First, PCa is a slow growing, with a doubling time of 3-4 
years. Secondly PCa is remarkably age related that rarely appears before 40 years of age 
and typically identified in men around 70 years of age.46 A Spanish study on 
Mediterranean men stated 33% of men in their 8th decade had evidence of PCa at 
necropsy and died with the disease, but not from it.47 Third, PCa usually is multifocal, so 
that most men with PCa die not just because of it but because of other cancers or disease 
conditions. Fourth, PCa and PIN are heterogenous in their morphology and genotype, 
virtually the entire genome participates in prostatic carcinogenesis.46 
2. 7 Progression
9 
The development of prostatic tumor in men is generally slow, taking up to 4 to IO 
years to develop a 0.4 inch-size tumor.48 Multiple molecular events have been associated
with the development of PCa. An early event in PCa progression is the loss of a region of 
chromosome 8p, which occurs in approximately 80% oftumors.49 Another step in PCa 
progression occurs with the loss of chromosome I Oq and the tumor suppressor PTEN 
(Phosphatase and Tensin deleted on chromosome IO), which accounts for 50% - 80% of 
prostate tumors, thus supporting the role of PTEN in PCa progression.50 A third common 
event in PCa progression that results in carcinoma is the loss of chromosome l 3q which 
includes Retinoblastoma tumor suppressor gene, that occurs in 50% of prostate tumors.51
Progression of PCa is also based on androgen-based pathways that continue to have a 
clinically significant role in the progression of castrate-resistant PCa. 52 Mostly all men 
eventually develop progressive disease following androgen deprivation therapy (ADT), 
leading to castrate-resistant PCa. 53-54 ADT might also be because of adrenal gland and 
testis that produce several enzymes involved in the synthesis of testosterone and 




The therapeutic approaches such as radical prostatectomy and radiotherapy are 
considered curative for localized disease, yet no treatments for metastatic PCa is 
available that can significantly increases patient survival. 56 PCa treatment is primarily by 
surgery and/or radiotherapy due to the intimate organ localization.48• 57 A prostatectomy 
usually leads to an excellent prognosis with low risk of death from PCa after surgery. 58
However, deregulated production and secretion of growth factors by stromal cells within 
the PCa microenvironment, as well as mutations in androgen signaling pathway 
components and further physiological modifications, including angiogenesis, local 
migration, invasion, intravasation, circulation, and extravasation of the tumor, potentially 
lead to systemic recurrence of the cancer, including the appearance of focal tumor in 
advanced stage. 59-63 Maximal therapeutic efficacy in the treatment of castration-resistant 
PCa will require novel agents or drugs that act by inhibition of the enzymes responsible 
for androgen production, as well as agents that inhibit the androgen receptor that target 
intracrine steroidogenic pathways within the prostate tumor microenvironment. 52 
2.9 Tumor Promoters in PCa 
Development of any neoplasm reflects a progressive and cumulative alteration in 
various genes. Oncogenes function in a dominant mode, whereas tumour suppressor 
genes (TSGs) are recessive.64 If the protein is over-active and contributes to prostate 
carcinogenesis, or metastasis, it could be termed a prostate-specific 'oncogene.64 Of the 
11 
oncogenes, the RAS gene tamily and neuroblastoma (N) RAS), have been most widely 
studied in PCa.65 C-ERB-B2 oncogene, as a tumor marker or therapeutic target remains
unclear in PCa. The MYC family of oncogenes, in particular C-MYC involved in 
differentiation has high level of mRNA in proliferating cells of PCa.66 The polycomb 
group protein, 'enhancer ofzeste homologue 2', is activated in advanced PCa that causes 
generalized reduction in transcription by increasing histone deacetylation via histone 
deacetylase-2.67 Members of the RAF oncogene family that encode serine/ threonine 
kinases, which activate the mitogen-activated Mitogen- activated protein kinases 
(MAPK) or Extracellular signal- regulated (ERK) kinases through direct phosphorylation 
are the other kind of genes that are also expressed in PCa. 68 
2.10 Tumor Suppressors in PCa 
PCa progression occurs due to the inactivation, deletion or mutation of tumor 
suppressor genes such as PTEN, p53, retinoblastoma (RB), which are notable tumor 
suppressors.69•73 RB was the first identified gene product to suppress cell division by
preventing cells in G 1 phase from entering S phase,74 Protein p53, named after the 53-
kDa gene product, is a nuclear phosphoprotein that can produce growth arrest at the GI­
S checkpoint, allowing DNA repair, 75 is frequently mutated in PCa. 76 PTEN which is the 
second most deleted gene after p53 has a protein phosphatases activity that can act as 
either positive or negative regulator during signal transduction or cell transformation and 
acts as a marker for metastatic progression.71• 77
�---
-- ---- ---- - - - --- -- -- - -- - - -- ---------
2.11 Tumor Suppressor: PTEN 
12 
PTEN is an enzyme that is found in almost every tissue in the body. As a tumor 
suppressor, its primary role is to stop cells from dividing. Inactivation of PTEN results in 
uncontrolled proliferation of cells leading to the growth of tumors. PTEN plays a major 
role in the development of the nervous system and has been implicated in diseases such 
as autism and brain development.78 Germline PTEN mutations are primarily found in 
80% of patients with the autosomal dominant Cowden disease (CS),79 80 and 60% of 
individuals with Bannayan-Riley-Ruvalcaba syndrome (BRRS) another autosomal 
dominant hamartoma syndrome.81 However, PCa has not been found associated with 
Cowden syndrome and germline PTEN loss, 82 perhaps providing credence to the 
understanding that loss of PTEN is a late event in PCa. 71
PTEN also known as MMACJ (mutated in multiple advanced cancers I) and 
TEP I (TGF- beta regulated and epithelial cell enriched phosphatase 1),83 is mutated in 
multiple advanced cancers and was identified in 1997 when cloned and mapped to I 0q23, 
a region undergoing frequent somatic deletion in tumors.84 Genome wide linkage analysis 
and loss ofheterozygosity (LOH) studies have also identified 10q23.3 as one of the 
potential PCa (PC) susceptibility loci, 85 which is often deleted in PCa. 
PTEN is also deleted or inactivated in many tumors such as renal, melanoma, 
prostate, breast, lung, bladder and thyroid.86 Both monoallelic and biallelic deletions of 
PTEN occur in PCa cell lines and non-cultured human prostate tumor specimens. 87
Decreased PTEN expression correlates with increased tumor grade, advanced disease 
stage and poor prognosis. Human PTEN promoter is GC rich and lacks TAT A box with 
13 
several transcriptional start sites that contain binding sites for transcription factors such as 
Specificity protein 1 (SP-I), Tumor protein p53 (p53), Centromere binding factor I 
(CBF-1 ), Snail family transcriptional factor l (Snail 1 ), Proto-oncogene Jun in humans 
(C-Jun), Early growth factor (Egr-1) and Activating protein 2 (AP-2) whereas Nuclear 
factor kappaB (NF-kB) and Peroxisome proliferator- activated receptor gamma (PPAR­
y) regulate PTEN expression.88 Mutation in PTEN gene can lead to protein formation but 
that PTEN is not active as it cannot dephosphorylate pAKT to AKT.89 PTEN can be 
regulated at different levels, transcriptionally, translationally post-translationally and also 
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Figure 3. Regulation of PTEN transcription. Numerous genes regulate PTEN transcription both 
positively (EGR-1, PPARy, Myc, and p53) and negatively (NFKB, c-Jun, HES, and TGF� signaling). 
NOTCH I may be able to activate or repress PTEN transcription depending on the cellular context. 
Recently, miR-21 wasidentified as the first microRNA to regulate the expression of PTEN. 
2.12 PTEN Structure 
PTEN is a 47 k.Da (403 aa) protein with nine exons. The PTEN amino acid 
sequence resembles dual specific protein phosphatases and tensin, a chicken cytoskeletal 
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C2 domain that mediates membrane attachment of cell signaling proteins. Other three 
functional domains of PTEN, include short phosphatidylinositol-4,5-bisphosphate (PIP2) 
binding domain on the N terminus, PEST sequences and a PDZ interaction motif on the 
C-terminal tail that regulate protein stability and binding to PDZ domain containing
proteins, are thought to be central to its biological functions.90 The phosphatase domain,
directly responsible for removing a phosphate group from the lipid PIP3, is evolutionarily 
conserved. Almost 40% of the cancer associated mutations in PTEN are found in the 
phosphatase domain.80 91 Tumorigenic mutations also occur on C-terminal C2 domain 
and tail sequence, highlighting the role of C terminus in maintaining PTEN protein 
stability.92 PTEN loss in PCa is commonly from somatic mutations generated through
copy number loss, rather than point mutation.93 With the absence of PTEN there is 
reduced survival in PCa patients.94
2.13 PTEN Localization (in the Nucleus) 
PTEN contains dual nuclear localization signal like sequences, regulate cell cycle 
progression and genomic integrity in the nucleus, 95 by inducing GI cell cycle arrest in 
part by reducing cyclin DI levels through its phosphatase activity,96 or through MAPK 
signaling.97 There is a marked reduction in nuclear PTEN in rapidly cycling cancer cells 
in comparison to resting or differentiated cells.98 Nuclear export of PTEN is inhibited by 
oxidative stress, a process dependent on phosphorylation ofSer380.99 p53 transcriptional 
activity and stability can be regulated by nuclear PTEN, independent of its phosphatase 
activity, leading to p53 mediated GI growth arrest and cell death.21· 100 Nuclear PTEN 
itself is sufficient to reduce human prostate xenograft growth in-vivo in a p53 dependent 
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manner.99 Nuclear expression of PTEN can reduce nuclear levels of pAKT, but whether 
this is a Pl3K dependent or independent mechanism is not known. 101 Through its 
phosphatase independent mechanism, nuclear PTEN increases the activity of RADS, a 
protein involved in double strand break repair, 102 and also increases E3 ligase activity of 
APC/C with its activator CDHJ, 103 that is involved in degrading oncogenic proteins 
PLK I and Aurora kinases. 104-105
2.14 PTEN and Regulation of the P13K/AKT/mTOR Pathway-PCa 
PI3K/ AKT pathway which is active in human cancers, controls cell growth, 
migration, differentiation and survival at cellular level. 106 The major substrate of PTEN is 
phosphatidylinositol (3,4,5)-triphosphate (PIP-3), a lipid second messenger molecule 
generated by the action of PI3Ks. PTEN by its lipid phosphatase activity removes 
phosphate from the D3 position of PIP3, thus antagonizing the action of PI3K, 107 and 
thereby stops cell division. In the absence of PTEN, PIP3 accumulates at plasma 
membrane. This results in the recruitment and activation of kinases such as 
phosphoinoside-dependent kinase I (POK I) and AKT that are involved in cell growth and 
survival via their pleckstrin homology (PH) domains. 101-108 AKT (isoforms 1,2, 3) which 
gets phosphorylated at Thr308 by POK!, 109 and Ser473 by mammalian target of 
rapamycin complex2 (mTOR), 110 drives cell survival, proliferation, growth, angiogenesis, 
and metabolism by phosphorylating downstream signaling proteins which include 
inhibitory phosphorylation of GSK3 beta, FOXO, BAD, p21, p27, and PGCI, and 
activating phosphorylation ofmTORI, IKK beta, MDM2, ENTPDS, SREBPIC, AS160 
and SKP2. 110-111 AKT promotes cell cycle progression and proliferation by inhibiting 
16 
and SKP2.110•111 AKT promotes cell cycle progression and proliferation by inhibiting
p21, p27 and alleviating GSK.3-beta induced cycl in D 1 degradation, 111-112 and can also
evade apoptosis by phosphorylating pro-apoptotic protein BAD. 113 mTOR signaling also 
triggers a negative feedback loop that inhibits PI3K/AKT pathway through 
phosphorylation that degrades insulin receptor substrate 1 by S6K.114 Conversely
inhibiting mTORl results in activation of PI3K/AKT pathway through RAS/MAPK 








Figure 4. AKT pathway: The solid arrows mark the directional change of proteins (up- or down­
regulation). Doted arrows mark hypothesized change in protein expression/activity. CDC42, cell division 
cycle 42; G3BP 1, GTPase-activating protein SH3-domain-binding protein 1; GDl-2, Rho GDP dissociation 
inhibitor 2; LIMK, LIM domain kinase; MAPK, mitogen-activated protein kinase; MCM7, 
mini chromosome maintenance protein 7; MSH2, MutS homolog 2; NORG I, N-myc downstream regulated 
gene I; p2 I, cyclin-dependent kinase inhibitor I A; PCNA, proliferating cell nuclear antigen; PI3 K, 
phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog; Rb, retinoblastoma protein; RhoA, Ras 
homolog gene family member A. 
ln both heritable and sporadic cancers, when PTEN is absent or dysfunctional, 
Akt phosphorylation and activity are significantly increased In vitro and In vivo.116 PTEN
inhibits phosphorylation of Akt, which, in turn, stimulates AR phosphorylation and 
domain/Hinge domain and inhibits AR nuclear translocation and AR-mediated 
transcriptional activity in PCa cells. 118
2.15 PI3K/AKT/mTOR- Independent Functions of PTEN 
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The PTEN C2 domain that lacks phosphatase activity can interact directly with 
p53 to enhance p53 mediated cell cycle arrest and apoptosis by promoting stabilization, 
acetylation and tetramerization of p53.21-22 And also the same domain can regulate cell 
motility. 119 PTEN inactivation increases the expression and activity levels of MDM2 a 
known p53 repressor by Pl3K/AKT dependent pathway,23 but when PTEN is present it 
upregulates p53 through translational mechanisms mediated by mTORCl. 12° Conversely, 
p53 can also regulate PTEN at the transcriptional level, 121 and in PTEN null mouse 
model, deletion of p53 accelerated PTEN null PCa by reducing cellular senescence. 122
PTEN also regulates NJOO. I, a tumor suppressor whose function is lost as an early event 
in PCa initiation. 123
2.16 Function of PTEN 
Lipid phosphatase activity of PTEN is important to its tumor suppressor role. 
PTEN as a dual specific phosphatase with activity towards acidic substrates, removes 
phosphates from both lipids and proteins and thus acts as a multifunctional protein. 84
Reconstitution of PTEN expression to certain PTEN null cells results in an increase in the 
population of cells at GI phase of the cell cycle,124 but in other PTEN null cells it resulted 
in the induction of apoptosis suggesting the evidence of lipid phosphatase activity of 
PTEN, 125 that is associated with tumor suppression. PTEN phosphatase activity can be 
inhibited by direct binding of DJ 1. 126 PTEN is also capable of dephosphorylating 
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phosphorylated serine, threonine and tyrosine residues on peptide substrates in vitro, 127 as
well as protein substrates such as FAK ,
128 CREB, 129 Elf2, 130 and SRC,131 in vivo, thereby
inhibiting cell survival, proliferation and migration. 
2.17 Transcriptional Role of PTEN 
PTEN is one of the most frequently mutated genes in cancer after p53, with 
inactivating mutations found in many solid tumor types. 132 The PTEN gene has been
shown to be inactivated through somatic and germline mutations as well as 
transcriptionally suppressed through epigenetic mechanisms, 133 and often lost in late­
stage human cancers, especially those of the brain, prostate and endometrium. 134
Epigenetic inactivation of PTEN expression has been described in cancer xenografts, 
where loss of PTEN protein is a result of promoter methylation. 50 Transcriptionally,
TGF-beta regulates PTEN expression depending on Ras/MAPK pathway. In late stage 
aggressive diseases, when Ras/MAPK pathway is active, TGF-beta suppresses PTEN 
through Smad4 independent pathway, 135 and also through c-Jun. 136 In the case when
Ras/MAPK pathway is blocked, TGF-beta induces PTEN expression through Smad 
dependent pathway. 137 Mitogen activated protein kinase kinase 4 (MKK-4) inhibits
PTEN transcripton by activating Nf-kB, a transcriptional suppressor of PTEN. 138
Epithelial to mesenchymal transition (EMT) transcription factor SNAIL, that negatively 
regulates PTEN expression competes with p53 to bind to PTEN promoter and leads to 
activation of PTEN transcription during p53 mediated apoptosis. 139-140 PTEN
transcription is also regulated by transcription factors such as PPAR-gamma, 141 EGRI, 142
BMJ, 143 whereas activated NOTCH! both positively and negatively regulates PTEN 
through MYC and CBFI. 144-145
2.18 Post-Transcriptional Role of PTEN 
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Post-transcriptionally, PTEN mRNA at miRNA loci is regulated by both miR-22 
and miR-106B-25 cluster, that are overexpressed in human PCa.146 PTENPI the PTEN 
pseudogene which shares vast homology with PTEN mRNA acts as a decoy for PTEN 
targeting miRNAs and therefore sequester and inhibit negative regulatory effects of 
miRNAs on PTEN mRNA, and thus PTENPI influence PTEN expression through a 
coding independent function. 147-148
2.19 Post-Translational Role of PTEN 
Post-translationally, in inactive state PTEN is phosphorylated at various serine 
and threonine residues on its C-terminal tail, that increases PTEN stability. 149 This 
modification reduces its plasma membrane localization, 150 and its ability to form complex 
with PDZ domain-containing proteins,151 and as a result there is a decrease in its PIP3 
lipid phosphatase activity. 152 Whereas when PTEN is dephosphorylated at C-terminal tail, 
it opens its phosphatase domain and interacts with binding partners, that makes PTEN 
more unstable, 153 and this open state is more prone to ubiquitin mediated proteosomal 
degradation at Lysl 3 and Lys289 that is mediated by NEDD4-1, E3 Jigase. 101- 154
Phosphorylation of different amino acids in C-terminal tail of PTEN has different effects 
and functions that are phosphorylated by different mechanisms. Ser3 70 can be 
phosphorylated by tyrosine protein kinase SRC, and protein kinase CK2, 155 while Thr366 
by GSK3-beta.156 Phosphorylation at Ser229 and Thr32 I targets PTEN to plasma 
membrane by protein kinase ROCK, 157-159 whereas phosphorylation at Tyr336 by RAK
can lead to its tumor suppressor activity. 160
2.20 Helix Loop Helix (HLH) and Basic HLH (bHLH) Proteins 
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The helix-loop-helix (HLH) family of transcription factors comprises >200 
members, which have been identified in organisms from yeast to man. 1-2 The basic helix­
loop-helix (HLH) family of transcription factors are key players in many developmental 
proccsses,3 such as differentiation in various cell types, such as in Band T-lymphocytes, 
muscle lineages, pancreatic B cells, neurons and osteoblasts.4-5 Most basic helix-loop­
helix (bHLH) proteins positively regulate sets of genes during cell fate determination and 
cell differentiation form a large super family of transcription factors that regulate tissue­
specific transcription.6 Members of this family have two highly conserved domains. The 
carboxyl terminal end of bHLH contains the helix loop helix (HLH) domain involved in 
forming a homo or hetero dimerization with other bHLH proteins that regulates 
transcriptional regulation and the amino terminal end contains the basic domain that 
binds to DNA sequences called E-box, 19 that plays a very important role in many 
physiological processes including cellular differentiation, apoptosis, cell cycle arrest and 
regulate critical developmental processes.7
2.21. Inhibitor of Differentiation/Inhibitor of DNA Binding (ID) Proteins 
Id proteins are typically expressed in highly proliferating cells and their 
expression levels decrease in differentiated cells. Ids are known to be positive regulators 
of cell growth and negative regulators of cell differentiation. 10 ID proteins play key roles 
in the regulation of lineage commitment, cell fate decisions, 11 and also have a role in cell 
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signaling, DNA damage control, and apoptosis. They also act in the timing of 
differentiation during neurogenesis, lymphopoiesis and neovascularisation (angiogenesis) 
and are essential for embryogenesis and cell cycle progression. 11 
HLH proteins that positively regulate sets of genes during cell fate determination 
and cell differentiation, possess a region high in basic amino acids adjacent to HLH 
domain, that facilitates binding to DNA containing the canonical 'E box' recognition 
sequence, CANNTG and 'N box' sequence, CACNAG, 2 or Ets recognition sequence, 
GGAA/T present in the promoter regions of regulated proteins,4 and thus form a large 
super family of transcription factors that regulate tissue-specific transcription.6 However, 
a distinct subfamily of HLH proteins, the ID proteins, lack these basic DNA-binding 
region and instead function solely by dimerization with other transcriptional regulators, 
principally those of the bHLH type and such ID-bHLH heterodimers are unable to bind to 
DNA, and hence ID proteins act as dominant negative regulators ofbHLH proteins.8 9.
Ids are known to interact with other bHLH proteins such as E2A, E2-2, or HEB, and also 
with factors such as RB (retinoblastoma) family members that have a role in cell cyclc.4
The Id family consists of four isoforms, Id I, Id2, Id3, and Id4,4 that act as negative 
regulators of basic bHLH transcription factors, by inhibiting the binding of ID-bHLH 
complex to DNA. Structurally, the core HLH domain between Id and bHLH proteins is 
highly conserved that allows efficient Id-bHLH dimerization. However, the ld-bHLH 
dimer is transcriptionally inactive due to the lack of DNA-binding basic domain in Id 
proteins 161 (see Figure 5). The interference of Id proteins with the key regulatory bHLH 
proteins is therefore an important interaction for proliferation and differentiation. 
22 
A 8 
Figure 5. bHLH transcription factors: Part A, represents Basic helix loop helix domain ofbHLH 
transcription factors containing DNA-binding domain. Part B, represents bHLH proteins that bind to DNA. 
Id proteins lacking DNA binding domain, binds to E-proteins, but the complex cannot bind to DNA. 
In man, the Id 1,Id2, Id3, and Id4 genes map to same chromosome at positions 20q 11, 162 
2p25,162 1p36 I63 , and 6p21.3-2212, where all of them share considerable homology to one
another and seem to have derived from a common ancestral gene. 164 
Widespread expression of Id 1, Id2 and Id3 genes was demonstrated throughout 
from early gestation to birth during mouse development, with considerable overlap of Id 1 
and Id3, with distinct ld4 expression limited to nervous system.165-166 Deletion ofldl 
gene in mice, failed to generate phenotype, and ld2 null mice possessed defects in 
immunity due to lack of lymph nodes, while mice null for Id3 had defects in B cell 
proliferation and humoral immunity.167-I68 Mice null for both Id 1 and Id3 possessed 
embryonic lethality with aberrant neuronal differentiation and angiogenesis. 169 Id 1, Id2 
and Id3 which are identified as mitogen responsive,3 are further implicated in cell cycle 
progression when antisense Id constructs are introduced into serum stimulated NIH3T3 
cells.3 Id 1 had shown to inhibit, E-protein and ETS mediated activation of the CDK 
inhibitor p 16/INK4a.170 ld2 and Id3 have been shown to get phosphorylated in late GI 
stage of cell cycle by cyclin dependent kinase 2 (CDK2), 171-112 and Jd2 by interacting via 
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its HLH domain with retinoblastoma protein (pRb ), p 107 and p 130, reverses cellular 
growth inhibition.3 Id proteins induce apoptosis in accordance with their expression. 
Expression ofldl in dense mammary epithelial cell cultures, 173 Id3 in B-lymphocytes, 174
and Id4 in astrocyte-derived cell line, 175 induces apoptosis. 
In general, the expression of Id proteins is high in proliferating cells as Id proteins 
(Jdl-Id3) promote cell proliferation, 10- 176 and expression is down regulated during 
differentiation. 177 Id I, Id2, and Id3 are upregulated are in pancreatic cancers, 178
colorectal cancers, 179 astrocytic tumors, 180 and squamous cell carcinomas of head and 
neck. 181 Id4 expression is seen to decrease in many cancers, 182 due to promoter hyper 
methylation, 183 except in testicular seminomas where all Id genes are upregulated. 184 As 
key regulators of cell cycle and differentiation. Id proteins have shown a vast regulatory 
function across diverse cellular functions including cell cycle, apoptosis, senescence and 
tumorigenesis in cancer. 185
ID2 and 1D3 contain an N terminal region targeted by Cyclin A and Cyclin E 
cdk2 complexes for phosphorylation, and that region is encoded by a Salmonella 
typhimurium virulence gene regulator (SPVR) site of which a serine residue is 
phosphorylated, the SPVR region is also present on ID4 but absent in ID! . 172
Phosphorylation of ID2 inhibits the binding to E proteins, whereas the phosphorylation of 
ID3 changes the specificity of the binding to either E 12 homodimers or E 12-MyoD 
heterodimers in B-cells. 171 The inhibition of the phosphorylation of either ID2 or ID3 also 
affects their ability to promote S phase entry and therefore affects the proliferative 
potential of the ID2 and ID3. 186 The half�life of the JD proteins varies between 15 
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minutes to !hour depending on cell type and cellular localization. 187 The degradation of 
the ID proteins has been linked to the ubiquitin proteasome system. This system relies on 
an ubiquitin activating enzyme, El, an ubiquitin carrier protein, E2, and an ubiquitin 
ligase, E3. The addition of multiple molecules ofubiquitin then targets the protein for 
degradation via the proteasome. 188 This process of degradation is apparent with ID 1, ID2 
and ID3, and also 1D4. However, ID4 that is ubiquitinated, is dependent on EI enzyme 
for degradation. 188 
2.22 Inhibitor of DNA Binding 4 (ld4) Protein 
Id4 mRNA and protein, which are primarily expressed in the nervous system, 189 
progressively decrease as the precursor cells proliferate in vitro and in vivo and do so 
more quickly when the cells are cultured at 33°C compared with at 37°C. The progressive
decrease in Jd4 transcription may be part of the cell-intrinsic timer that helps determine 
when oligodendrocyte precursor cells withdraw from the cell cycle and differentiate. 190 
The human 1D4 has two coding exons and produces a protein predicted to be 
approximately l 7kDa. In mice, ld4 RNA is expressed predominately in developing and 
mature neuronal tissue, bladder and bone marrow that differs from the expression 
patterns ofldl, Jd2 and [d3, 189 while low levels ofld4 RNA (with all the other ID 
transcripts) is seen in in vitro embryonic stem cell line cultures, but this disappeared as 
the cells differentiated into blast colonies. 191 
1D4 expression in PCa is associated with an increased risk ofmetastasis. 192 A
recent study by Sharma et al. found Jd4 promoter methylation in PCa. 183 Another study 
from our lab shows, ectopic expression ofld4 results in cell cycle arrest. 19 Id4 promoter 
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methylation and loss of expression has also been documented in colorectal 
adenocarcinomas. 193 Id4 expression has been linked to breast tumourigenesis and Id4 
protein down-regulates BRCAJ expression, 194 and its expression is inversely correlated 
with estrogen receptor expression in breast cancer malignancies. 195 ld4 promoter 
methylation which is evident in breast cancer demonstrates its role as a potential tumour 
suppressor and oncogene in a context dependent manner. 196 
The sub-cellular localisation of the Id proteins is considered nuclear, but differs 
with cell type, differentiation stage and post translational modification. 197 In normal rat 
breast tissue ld4 sub-cellular localisation changes with the differentiation stage of the 
epithelia, with more nuclear staining in proliferating epithelia and in all other stages it is 
either mostly cytoplasmic or very weakly expressed. 198 In PCa cell lines, it shows that ld4 
protein has a different effect on the cell cycle to the other Id proteins. Id4, when 
ectopically over-expressed in PCa cell lines, induced S phase arrest and apoptosis and 
this was attributed to Id4 up-regulating the expression of E2A which in tum increased the 
levels ofp21 andp27 expression. Id4 has also been demonstrated to increase cyclin e 
levels in cdkn2a -/- astrocytes, which drives their proliferation. 199 In neural precursors, 
Id4 protein is required for the GI to S phase transition in the cell cycle.200
ld4 plays an important role in nervous system and in particularly in 
oligodendrocyte differentiation by directly binding to OLIG I and OLIG2 proteins 
responsible for in neural progenitor cells, 201•202 and acts as a tumor suppressor in breast 
cancer.203 The specific nature ofld4 protein expression in cancer has not been clarified, 
however studies support that Id4 has both pro-tumor and anti-tumor activity. Epigenetic 
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silencing ofld4 in leukemia,204 breast, 196· 205 colorectal,206 mouse and human chronic
lymphocytic leukemia (CLL),207 and gastric cancer,208-209 tend to support its antitumor
activity. It is highly expressed in bladder and rat mammary gland carcinomas suggesting 
that it may have pro-tumor activity.210 All knockout Id4 mice studies revealed that ld4
plays an essential role in neural stem cell proliferation and differentiation,200 and normal
brain development. 211
The t(6;14)(p22;q32) translocation was initially identified using fluorescence 'in 
situ' hybridization (FISH) and inverse PCR in one case of adult B cell precursor acute 
lymphoblastic leukaemia (BCP-ALL) and showed ID./ RNA expression,212 and also over­
expression of 104 protein by immunohistochemical staining in four other cases of BCP­
ALL which harboured other genetic abnormalities such as a t(8;14) translocation, a P53
mutation, 46XYI 2p- and hyperdiploidy. 
The involvement of ID./ in an immunoglobulin heavy chain locus (IGH) 
translocation was identified in 13 patients with BCP-ALL.210 The t (6;14) (p22;q32) was
cloned from 3 cases using long distance inverse PCR (LDI-PCR) and showed the 
translocation of IGHJinto the centromeric 3' portion of the ID./ gene resulting in the 
over expression of ID4 RNA in BCP-ALL. The current literature and preliminary gene 
expression experiments therefore suggest that ID-I may be a tumor suppressor or an 
oncogene in a context dependent manner. 
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2.23 Id4 Expression in Normal Prostate 
Oncomine database suggested that Id4 is highly expressed in the lurninal 
epithelial cells of the adult normal prostate and its expression decreases in PCa (Figure 6) 
and that was also seen in mouse prostate (Figure 7). To further elucidate this 
phenomenon, a tissue microarray (TMA) also showed that Id4 is highly expressed in 
normal prostate whereas its expression decreases with increase in cancer progression 
(Figure 8). Majority of studies have suggested that Id4 acts a potential tumor suppressor 
in many other cancers such as breast, leukemia, glial neoplasia, gastric cancer, pancreatic 
cancer, colorectal adenocarcinoma, and malignant lymphoma. 
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Figure 8. PCa tissue microarrays. They were used to investigate ld4 expression. ld4 was highly 
expressed in normal prostate (A) 200X and (B) 400X as seen by intense brown staining in the nuclei. 
Overall, ld4 expression decreased with increasing grade of PCa (C) grade I (200X), (D) grade I (400X), (E) 
Grade JI (200X), (F) grade II (400X), (G) Grade lil (200X), and (H) Grade Ill (400X). The sections are 
also representative of scores used to quantify staining intensity: A and B - score 3; C and D - score 2; E -
score 0. ld4 is mostly nuclear as seen by intense nuclear staining (brown, indicated by red arrow in D). At 
higher stages a clear large nucleus with no apparent brown staining is observed (yellow arrow in D and F). 
The sections were counterstained with hematoxylin that is reflected in the blue nuclei observed primarily in 
PCa sections with undetectable Jd4 expression. The 400X images in panels B, D, F, and H are 
corresponding images of boxed regions shown in panels A, C, E, and G (2009). The inset in panel G is the 
4009 image of the region showing high ld4 expression in normal prostate adjacent to cancer (stage III). 
2.24 Id4 is Epigenetically Silenced in Cancer 
Studies performed in other cancers such as breast, colorectal and lymphoma have 
showed that Id4 is epigenetically silenced due to promoter hyperrnethylation. EZH2 is a 
transcriptional repressor that plays a vital role in maintaining the homeostatic balance 
between gene repression and expression.213 In PCa EZH2 is involved in epigenetic 
silencing of many tumor suppressor genes such as DAB2 interacting protein 
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Figure 10. Treatment with NaBr: Relative expression levels of Annexin and ld4 gene levels increased in 
dose dependent manner when treated with Na Br in DU I 45 cells. Annex in is used as positive control for the 
treatment. 
2.26 Id4 Acts as a Tumor Suppressor 
The specific nature of Id4 protein expression in cancer has not been clarified, 
however studies support that Id4 has both pro-tumor and anti-tumor activity. Epigenetic 
silencing ofld4 in leukemia,20
4 
breast, 203 colorectat,206 mouse and human chronic
lymphocytic leukemia (CLL),207 and gastric cancer,208 tend to support its antitumor 
activity. 
PCa by promoting apoptosis through caspase 3/7, cytochrome c and p53 
dependent pathways. 16• 19 Also, we have shown that Id4 promotes senescence by 
promoting E2F I expression. 16 Id4 has also been shown to attenuate cell proliferation by 
increasing the expression of cyclin dependent kinase inhibitors p 16 and p27 expression 
and inhibits migration by down-regulating MMP2 expression.221 Nkx3. l, a marker of 
epithelial differentiation that regulates rate of proliferating luminal epethilial cells in 
prostate,222 is downregulated in LNCaP - Id4 cells, (Id4 was silenced with gene specific 
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shRNA) whereas it is upregulated in DU145+Id4 cells (Id4 is ectopically expressed). 
PTEN that acts as a negative regulator of AKT is upregulated in DU145+Id4 cells. 18 
Sox9 whose expression is observed in early stages of prostate hyperplasia and is a part of 
prostate development that gets reactivated in prostate neoplasia is upregulated in LNCaP­
ld4 cell and vice versa in DU145+1d4 cells.223-224 Our studies from lab show that Id4 
overexpression in DU 145 cells promoted apotosis and scenecence (Figures 11 and 12). 
Overall these studies show that in PCa cell models, in which Id4 was either silenced or 










Figure: 11. ld4 induces apoptosis in DU 145 cells. DU 145 + ld4 cells have almost three times more 
apoptotic cells than DU 145 cells, along with more 50% more dead cells 
Cells B-gal Staining
Figure: 12. ld4 promotes senescence in the DUl45 cells. Cells (DU 145 and DU 145+ld4) cells were 
stained with SA-b-galactosidase. The blue nuclei due to SA-b-galactosidase staining were counted in 15 
randomly-selected fields and are expressed as mean+SEM (panel F). The flattened nuclei with intense blue 
staining were classified as cells with advanced senescence and smaller light blue nuclei were counted as 
cells with moderate senescence. ***p<0.00 I, t-test performed for columns "a" and "b" 
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2.27 PTEN/AKT Pathway and ld4 
Study between ld4 and PTEN expression, suggest that there is some cross-talk 
between AKT pathway and Id4. 18 Recent study by Sharma et al suggested that loss ofld4
in mouse prostates resulted in decrease in expression levels of PTEN and vice-versa 
pAKT expression levels increased in the absence of ld4 suggesting its role in the AKT 
pathway. In Id2 and ld3 the serines in Salmonella typhimurium virulence gene regulator 
(SPVR) site are being phosphorylated.26 Id2 acts as a growth suppressor in myoblasts 
when one of its serine at position 5 in SPVR region gets dephosphory lated. 26 ld4 also 
possess similar sequence containing the serine's at the same positions as seen in ld2. So 
these findings led us to investigate whether Id4 functions in the similar fashion as Id2. 
From previous study, 18 and from preliminary studies (data shown below) we know that 
ld4 plays a role in regulating PTEN and pAKT expressions. 
p53 binding to PTEN promoter can enhance the regulation of PTEN by ld4 and 
thus can mediate cell cycle arrest and apoptosis by promoting stabilization, acetylation 
and tetramerization ofp53.2 1·22 ld4 that regulates PTEN activity and expression, might
play a role when PTEN inactivation increases the expression and activity levels of 
MDM2 a known p53 repressor by PBK/AKT dependent pathway23 , but when PTEN is 
present it upregulates p53 through translational mechanisms mediated by mTORCI. All 
this studies along with some bioinformatics studies made us to investigate the role of 
PTEN/ AKT pathway in regulating Id4 phosphorylation and vice-versa the role ofld4 in 
regulating PTEN/AKT pathway. 
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2.28 ld4 Regulates PTEN/ A.KT Pathway 
IHC studies on prostates from 6-8 weeks old ld4-/- mice were analyzed. Data 
suggested the loss or decreased PTEN expression in Jd4-/-prostates as compared to wild 
type. f n Id4 -/-, expression levels of pAKT increased compared to wild type with no 
significant change in AKT levels. Jd4 -/- leads to PIN like lessons suggesting ld4s role in 
PCa initiation and progression as shown in Figure 13. These results lead us to investigate 
AKT, pAKT and PTEN mRNA and protein levels in PCa cell in context ofld4 
expression. 
Fi2ure 13. IHC data on PTEN, AKT and phospho-AKT (p-AKT). Expression in wild type (ld4+/+) and ld4 
knockout (ld4-/-) mice A: Pten was expressed at high level in the normal prostate both m the nucleus and cytoplasm of ld4+/+ 
prostate. B and C: Ptcn expression was significantly reduced or undetectable (black arrowheads) in the ld4-/- prostate ducts. Note the 
hyperplastic regions in Panel B. Occasionally, few Pten positive cells were observed that were primarily localized to epithelial cells 
near the basement membrane (Inset in Panel B). Ptcn expression was observed in the urethra (asterisk, Panel C) but not in prostatic 
ducts. The inset in Panels A and B arc enlarged boxed regions m corresponding panels. Panels D-F: Lobe specific expression of 
phospho-Akt in ld4-/- mice. Increased phospho-Akt was observed in dorsal prostate (Panel D) but not in ventral (E and inset)) and 
lateral ( F) prostate. Phosphorylation of Akt correlated with total Akt expression (G-1) m ld4-/- prostate. Akt expression was 
undetectable m lateral and ventral prostate (G) but was detectable in dorsal prostate (II and I) from ld4-/- mice. Panels J-L: Total Akt 
expression in wild type mice prostate. Aki expression was highly variable within the glandular epithelium (J). Regions of undetectable 
to high Akt expression ,1cre juxtaposed ( K and L) Similar expression profile (low to high) of phospho-Akt was observed m ,1 lid type 
prostates (Panels M-0). The cells stammg positive for phospho-Akt ,1erc counted in tubules that also stained pos111ve for Al..t. The 
ratio of pAkt/Akt positive cells is shown in Panel L ( .. •: P < 0.00 I). Representative images are shown. The scale bar is I 00 um 
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In comparision with DU 145 cell line, in DU l 45+ld4 (Id4 ectopically expressed), 
pAKT levels decreased and AKT levels remained the same as seen in Figures 14, 15, and 
16. PTEN levels increased, in DU145+Id4 as compared to DU145 cells, suggesting that
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Figure 14. PTEN mRNA data. Showing increase in PTEN expression in the presence ofld4 in RT PCR. 
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Figure 15. PTEN protein expression. Data showing increase in PTEN expression in the presence of ld4 in 





Figure 16. Expression levels ofphospho AKT and AKT. LNCaP- ld4 cells show more expression of 
pAKT when compared to LNCaP cells. DU 145 + Id4 cells have less expression pAKT when compared to 
DU 145 cells. Total AKT remained similar in comparative cell lines. GAPDH was used as a loading control. 
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Till now, no studies have been performed to address the mechanism by which Id4 
act as a tumor suppressor (Prostate) or tumor promoter (Glioblastoma). All Ids have 
conserved HLH domain with variables C and N terminals as shown in Figure 17. Id2 
which belongs to the same family as Id4 is known to act as tumor promoter when it is 














Figure 17. ID protein sequences. Conserved HLH domain in all Id proteins shown in Red box. Yellow box 
is the serine at position 5 that is phosphorylated in ld2 and present in ld4. 
Analysis of data from different Bioinformatics tools like NET PhosK 1.0 Server 
(Figure 18) predicted the possible phosphorylation sites in Id4. This results along with the 
role Id4 role in regulating phospho-AKT via PTEN prompted us investigate the role of 
PTEN/AKT pathway in Id4 phosphorylation. Thus these findings led us to propose a 
model (Figure 19) whereby, Id4 could regulate PTEN/AKT pathway via phosphorylation. 
Collectively, the initial data prompted us to investigate the role of Id4 in regulating PTEN 
and AKT pathway, and whether this study can answer the Id4 form of action in PCa is 
through phosphorylation or not. 
NetPhosK 1.0 Server - prediction results 
Technical University of Denmark 
Meehod: �eePho•K w1ehoue ESS r11eerino: 
Quer¥= q1_ee1546_qb_AAA73923.1_ 
S.1.ee Kinase Score 
---------------------
S-5 cd.lc5 0.61 
s-10 PKC o.�e 
S-16 c<Sc2 0 . 53 
S-3 .. ed.c.2 0.50 
S-73 PKC 0 . 5.!! 
=-:e� PKC 0.66 
.S-:!:9 PKA 0 .56 
s-e9 PKG 0. 56 
T-130 PRC o.e2 
T-13!!. p33MAPK o.s�
T-138 GSK3 0.51 
T-13!! ed.k'S 0 .5 .. 
T-1 .. S cde2 0. 50 
---------------------
H1.Qh�.3e Score: 
Figure 18. NetPhosK 1.0 Server. Showing ld4 Predicted phosphorylation sites with highest score at 






Ex: Prostate Cancer 
Figure 19. Predicted ld4 phosphorylation model: This graphical representation shows possible 
phosphorylation of ld4. In the presence of PTEN. pAKT is converted back to AKT leading to 
dephosphorylation of Id4, that now acts as a tumor suppressor as seen in PCa. In the absence of PTEN, 
AKT gets phosphorylated and as result it leads to ld4 phosphorylation, that now acts as a tumor promoter 
as seen in Glioblastoma. Now ld4 that is in dephosphorylated form intum upregulates PTEN vice-versa, 
thus forming a positive feedback loop. 
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CHAPTER III 
MATERIALS AND METHODS 
3.1 1D4 Overexpression and Silencing in PCa Cell Lines 
The PCa cell lines LNCaP, DU145 and PC3 were purchased from ATCC and 
cultured as per A TCC recommendations. Human Id4 was over-expressed in DU 145 cells 
as previously described. 19 ID4 was stably silenced in LNCaP cells using gene specific 
sh RNA retroviral vectors (Open Biosystems #RHSl 764 -97196818, -97186620 and 
9193923 in pSM2c, termed as Id4shRNA A, Band C respectively). The cells transfected 
with non-silencing shRNA (RHS 1707) was used as control cell line. Transfections and 
selection of transfectants (puromycin) were performed as suggested by the supplier. 
Successful ID4 gene silencing was confirmed by qRT-PCR, Western blot analysis, and 
ICC. 
The pCMV + ID4 vector and pCMV vector alone was transfected in sub­
confluent (60%) PC3 cells grown in six well plates using Trans!T-prostate transfection 
reagent cocktail (IO µL Trans!T prostate reagent, 5 µL prostate boost reagent (Mirus Bio) 
and 2 µg pCMV-Id4 DNA in 200 µL of serum free media) for around 5 to 6 hours. The 
culture media which was without serum and antibiotics was changed. Once after an 
overnight that is after 12 hours incubation with the cocktail. Forty-eight hours after 
transfection, the cells with incorporated pCMV + ID4 were selected by incubation in the 
fresh media containing antibiotic named G4 I 8 with about 15 to 20 days with changing 
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fresh media containing 350 µg/mL 0418 (Invitrogen) for one week with media change 
every 2 days. Following this selection cycle, the transfected cells were passaged once in 
F12-BCS-Antibody and then re-exposed to F12-BCS-Antibody with 350 µg ofO418/ml 
for an additional week (second 0418 selection). This approach ensured the survival of 
only transfected cells. Simultaneous experiments were also performed in which cells 
were transfected with no DNA (control, parental) or with pCMV DNA (transfection 
control). The 0418 selection procedure described above resulted in no surviving PC3 
parental cells. The cells were grown to confluence (80%), trypsinized (0.25% v/v trypsin 
and 0.03% w/v EDT A in calcium- and magnesium free phosphate buffered saline), 
counted, and plated at a l :2 dilution in new l 00-mm plates. 
3.2 Reverse Transcriptase 
RNA (2 µg or 4µg) was reverse transcribed in a final volume of 25 µl as per 
standard protocols 18· 225 (RT-Mix: 1.25 mM each of dNTP's; 250 ng oligo dT (Promega, 
Madison, WI), IO mM dithiothreitol, and 200 U MML V reverse transcriptase 
(Invitrogen) in the MMLV first-strand synthesis buffer (lnvitrogen)). RNA was denatured 
for 10 min at 65°C, and then cooled on ice for 2 minutes before addition of RT mix and 
enzyme. The reverse transcriptase reaction was carried out at 42°C for l h and 95°C for 5
minutes. The reverse transcribed RNA were stored at -20°C until further analysis. 
3.3 Quantitative Real Time PCR (qRT-PCR) 
qRT-PCR was performed as described previously using gene specific primers 
(Table 2) on RNA purified from cell lines.226
Table 2. qRT-PCR and ChIP Primers Used in the Study 
PCR primers Forward (5' ) 
ld4 CCCTCCCTCTCTAGTGCTCC 























Total cellular proteins were prepared from cultured PCa cell lines using M-PER 
(Thermo Scientific). 19 Protein samples were quantitated using the BCA protein assay 
protocol from Bio-Rad. A standard curve was determined using BSA and sample 
absorbance read at 750 nm. Samples were concentrated in 30 µg/µL volume and then 
mixed 1: 1 with 2X laemmli sample Buffer. 
3.5 Western Blot Analysis 
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30 µg of total protein was size fractionated on 4-20% SDS-polyacrylamide gel 
and subsequently blotted onto a nitrocellulose membrane (Whatman). The blotted 
nitrocellulose membrane was subjected to western blot analysis using respective protein 
specific antibodies (Table 3 ). 
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Table 3. Antibodies for Western Blotting, Co-IP, IHC, ICC, and ChiP Analysis 
Protein Company Antibodies Dilutions WB/ICC 
!04 Aviva I: 1200, I :200 
!04 BioCheck 1:1000 
GAPDH Cell Signaling 1:1000, 1:200 
PUMA Rockland lmmunochemical 1:1000 
BAX Cell Signaling 1:1000 
PTEN Abeam 1:1000, 1:150 
p21 Cell Signaling 1:1000 
p53 Cell Signaling I: 1000, I :200 
E-Cad Novus Biologicals 1:1000 
AR Santa Cruz 1:500, 1:150 
EGFI Cell Signaling 1:1000 
Kl67 Abeam 1:1000 
RNA Pol II Millipore 
Global Acetylated lysine Cell Signaling 1:1000 
K320 Millipore 1:1000 
K373 Abeam 1:1000 
Goat anti-rabbit 1:10000 
Secondary Antibody Millipore 
PDH Cell Signaling 1:250 
ICC secondary antibodies Cell Signaling 
DyLight 594 goat anti- 1:200 
mouse (red) Thermoscientific 
DyLight 488 goat anti- 1:200 
rabbit (green) Thermoscientific 
DyLight 594 goat anti-
1:200 
rabit (red) Thermoscientific 
Dy Light 488 goat anti-
1:200 
mouse (green) Thermoscientific 
After washing with Ix PBS, 0.5% Tween 20, the membranes were incubated with 
horseradish peroxidase (HRP) coupled secondary antibody against rabbit JgG and 
visualized using the Super Signal West Dura Extended Duration Substrate (Thermo 
Scientific) on Fuji Film LAS-3000 Imager. 
3.6 Cell Proliferation Assay 
PC3-CMV and PC3+1D4 cells were plated in a U shaped 96 well plate at a 
density of 5x 103 cells/well. After the cells attached, they we Cell proliferation analyses 
were performed using 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay. PC3-CMV and PC3+ID4 cells were seeded in 96-multi well plates at a 
density of 5 x 105 cells/ well without serum overnight. Cells were then cultured for 72 
hrs. MTT assay was performed using CellTiter 96 Non-Radioactive Cell Proliferation 
Assay kit (Promega) following manufacturer's instructions. 
3. 7 Statistical Analysis (Proliferation)
Data was analyzed by SPSS 13.0 statistics software. Experimental data is 
presented as means ± SEM. A p-value of <0.05 was considered statistically significant. 
3.8 Apoptosis Assay 
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Apoptosis was quantitated using Propidium Iodide and Alexa Fluor 488 
conjugated Annexin V (Molecular Probes) and dual-sensor MitoCasp (Cell Technology) 
as described previously.227
3.9 Statistical Analysis {Apoptosis) 
Quantitative real time data was analyzed using the delta delta Ct method. The 
ChIP data was analyzed using% chromatin (1 %) as input (Life Technologies). Within 
group Student's t-test was used for evaluating the statistical differences between groups. 
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3.10 AKT Kinase Assay 
Akt kinase assay was performed using a nonradioactive IP-kinase assay kit (Cell 
Signaling, Beverly, USA) as directed by the manufacturer. Briefly, immunoprecipitated 
Akt was incubated with cold ATP and GSK-3 fusion protein, an AKT substrate, followed 
by detection ofphosphorylated GSK-3 by immunoblotting with a specific antiphospho­
GSK-3<>1/3 (Ser2l/9) antibody,228 in DU145 and DU145 + Id4 cells. 
3.11 Migration Assay 
In vitro cell migration assay was conducted using 24-well transwell inserts (8mm, 
BD Biosciences, Palo Alto, California). Cells were harvested and centrifuged at 1500 
rpm for 5 minutes at room temperature. The pellets were suspended into Fl2 
supplemented with 0.2% BSA. Aliquots of lOOµL cell suspension (3xl04 cells/insert) 
were added to each insert. Chemo attractant solutions were made by diluting EGF (I 0 
ng/mL) into Fl2 supplemented with 0.2% BSA and then cells were allowed to migrate 
through a porous membrane coated with rat tail collagen (50 mg/mL) at 37°C for 5 hours. 
F-12 containing 0.2% BSA served as the control medium. Cells inside the transwell
inserts were removed by cotton swabs. The cleaned inserts were fixed in 4% 
paraformaldehyde (pH 7.5). Cells on the outside of the transwell insert membranes were 
stained using DAPI (3 µg/mL). The images were captured in five random areas using 
Axiovert 200M, Carl Zeiss (Gottingen, Germany) microscope. Stained nuclei were 
counted using image analysis software (ZEN 2012; Carl Zeiss). Results were expressed 
as migration index defined as: the average number of cells per field for test substance/the 
average number of cells per field for the medium control. 
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3.12 Tunel Assay 
The terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate 
(dUTP) nick end labeling (TUNEL) assay was used to detect fragmented DNA as marker 
for apoptosis in FFPE tissue sections using T ACS 2 TdT-DAB apoptosis detection kit 
(Trevigen). The slides were counterstained in hematoxylin and mounted with lmmuno­
mount (Thermo Scientific). 
3.13 Luciferase Reporter Gene Assay 
PC3-CMV and PC3+1D4 cells were plated in a 96-well plate at a density of 
2.5x l 04 cells/well. After the cells attached, they were transiently transfected by mixing 
either mutated androgen response element (ARR3-luciferase) or AR response element 
driven luciferase reporter plasmid (PSA-luciferase) with pGL4.74 plasmid (hR/uc/TK: 
Renilla luciferase, Promega) DNA in a 9:1 ratio with FuGENE HD transfection reagent 
(Promega) in a final volume of l 00 µL of RPM! 1640 medium and incubated for 15 
minutes at room temperature. The transfection mix was then added to the cells followed 
by addition of R 1881 (IO nM) or vehicle after 4 hours. After a total of 24 hours, the cells 
were assayed for firefly and renilla luciferase activities using the Dual-Glo Luciferase 
reporter assay system (Promega) in LUM!star OPTIMA (MHG Labtech). The results 
were normalized for the internal renilla luciferase control. Both of the luciferase plasmids 
were provided as a generous gift from Dr Amina Zoubeidi (University of British 
Columbia, Canada). 
3.14 lmmunohistochemistry (IHC) 
Slides were processed through standard protocols. Following antigen retrieval 
(autoclave in 0.01 M sodium citrate buffer pH 6.0 at 121C/20 psi for 30 min), the 
peroxidase activity was blocked in 3% H2O2 and nonspecific binding sites blocked in 
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I 0% Goat serum. The blocked sections were incubated overnight at 4°C with respective 
protein specific primary antibodies followed by incubation with secondary antibody for I 
hour. The slides were stained with DAB for 2 min, counterstained with haematoxylin and 
mounted with lmmuno-mount (Thermo Scientific), examined and photo-micrographs 
taken using the Zeiss microscope with an AxioVision version 4.8 imaging system. All the 
antibodies were mono-reactive, that is a single reactive band was observed in western 
blot using total cell lysate from PCa cell lines LNCaP, DUI 545 and PC3. 
3.15 DNA Methylation Analysis 
PTEN promoter methylation was analyzed using methylation-specific PCR (MSP) 
as described previously.229 The MSP region amplified in context of the PTEN genome in 
this study has been previously investigated and well characterized in hepatocarcinoma.229
Briefly, Genomic DNA from cell lines was isolated using DNeasy kit (Qiagen) and from 
laser captured sections using ZR Genomic DNA tissue MicroPrep Kit (Zymo Research). 
Approximately I µg of DNA was sodium bi sulfite-modified using EZ DNA methylation 
Kit (Zymo Research) and subjected to MSP as described previously.229 Polymerase chain 
reactions were performed in a 25µL reaction using GoTaq Green master mix (12.Sul, 
Promega) with 500pm each of the 5' and 3' primers (Table 2). Temperature conditions 
for PCR were as follows: 40 cycles of 94°C for 30 sec, 58°C for 45 sec and 72°C for 30 
sec, followed by I cycle at 72°C for IO min. PCR products were separated on 1.5 % 
agarose gels and visualized using GelDoc XR+ (BioRad). 
3.16 Bisulfite Sequencing 
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Direct bisulfite sequencing of the PCR product was performed as reported earlier 
using ID4 specific primers as listed in Table 2 and analyzed using ABI sequencer. 
3.17 siRNA Transient Transfections 
Cells were seeded in 6 well plates at l .25x 105 cells/well in 5% bovine calf serum 
(VWR) and allowed to attach overnight. The following day, cells were rinsed with serum 
free media immediately prior to transfection. Transient transfection reagent was used to 
transfect pl 4ARF siRNA and p 14ARF siRNA (Catlog # AM51331) control in DU 145 
cells according to manufacturer's protocol from Ambion Life Technologies and the cells 
were then cultured for additional 48-72 hr. Subsequently, the transiently transfected cells 
were harvested for RNA/protein or cross linked with formaldehyde for Chromatin 
immuno-precipitation. 
3.18 Chromatin Immunoprecipitation (ChIP) Assay 
Formalin-fixed paraffin-embedded (FFPE) samples were used for Ch!P based 
analysis for enrichment ofp53, Acetyl p53, H3K27Me3 and H3Ac on PTEN promoter. 
For this analysis, the regions showing >75% cancerous regions or more than >80% 
normal/ benign regions were dissected using Leica LMD6500 and captured in micro 
centrifuge tubes. Genomic DNA was isolated from these sections by the method of 
Fanelli et al., except that tissue samples were de-paraffinized with xylene instead of 
histolemon. The chromatin extracted from tissue samples was sheared (Covaris S220), 
subjected to immuno-precipitation with either p53, Acetyl p53, RNA POL 11, 
H3Acetylation or IgG antibodies (see Table 3), reverse cross linked and subjected to 
quantitative Ch!P- PCR (qChlP). 
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Chromatin immuno-precipitation in cell lines was performed using the ChJP assay 
kit (Millipore, Billerica, MD) as per manufacturer's instructions. The chromatin (total 
DNA) extracted from cells was sheared (Covaris S220), subjected to immuno­
precipitation with respective antibodies (see above), reverse cross linked and subjected 
to quantitative ChIP- PCR in Bio-Rad CFX. 
3.19 Statistical Analysis (ChlP) 
Quantitative real time data was analyzed using the ti.ti.Ct method. The ChlP data 
was analyzed against non-immune IgG used as a negative control. Within group 
Student's t-test was used for evaluating the statistical differences between groups. 
3.20 lmmuno-Cytochemistry 
Cells were grown on glass chamber slides up to 75% confluency. The slides were 
then washed with PBS (3x) and fixed in ice cold methanol for 10 min at room 
temperature and stored at -20°C until further use. Before use, the slides were equilibrated 
at room temperature, washed with PBS (5 min x 3), blocked with I %BSA in PBST for 30 
min at room temp and incubated overnight ( 4°C) with primary antibody (I% BSA in 
PBST). The slides were then washed in PBS and incubated with secondary antibody with 
fluorochrome conjugated to Dy Light in I% BSA for I hr at room temp in dark. The 
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slides were subsequently washed again and stained in DAPI for I min and mounted with 
glycerol. Images were acquired by Zeiss fluorescence microscope through Axiovision 
software. 
3.21 Site-Directed Mutagenesis 
In-vitro site-directed mutagenesis was performed by using cloned Pfu DNA 
polymerase (Agilent technologies) on bacterial expression plasmids. The PCR product 
was first digested overnight with Dpn-1 (Promega) and then used to transform JMlOI 
super-competent cells (Agilent). All the mutants were verified by DNA sequencing 
(Applied Biosciences). Mutations in the SPVR region at serine 5 of!D4 were introduced 
by PCR using complementary primers incorporating specific site mutations. The 
mutation of the serine with alanine serves as a phospho- deficient and mutation of serine 
with glutamic acid serve as a phosphor- mimic. Followed by transfection of the plasmid 
into cell lines to further determine the effect of mutagenesis at serine 5 of ld4 that 
explains whether Id4 is phosphorylated or not. 
CHAPTER IV 
RESULTS 
4.1. ld4 Regulates PTEN Expression/Function 
Previous studies from both our lab and from other labs showed that ld4 acts as a 
tumor suppressor in PCa by promoting apoptosis through caspase 3/7, cytochrome c and 
p53 dependent pathways. 19 But the underlying mechanism of how Id4 regulates p53 
dependent pathways is not known. Studies showing the positive feedback loop between 
PTEN and p53 lead us to investigate one of the mechanisms of how p53 pathway can be 
regulated by PTEN in the presence ofld4. PTEN presence blocks the PI3-AKT pathway 
which controls fundamental cellular processes such as cell survival and cell cycle. In my 
preliminary data I have shown that ld4 increases the expression levels of PTEN and also I 
have shown that decreases pAKT expression levels with no change in total AKT levels. I 
have seen both at gene, protein and also with IHC data. These lead us to investigate the 
mechanism by which ld4 regulates PTEN expression/function and whether 
transcriptional regulation of PTEN is (acetyl) p53 dependent. ld4 acts as a tumor 
promoter in glioblastoma,230 but tumor suppressor in prostate, gastric, colon and 
leukemia. Functional difference of Id4 in different cancers might be because of 
phosphorylated or unphosphorylated forms as seen in the case of Id2. Recent evidences 
based on the Bioinformatics data on Id4 suggested possible phosphorylation sites that 
might get phosphorylated. PTEN by converting PIP3 to PIP2, (dephosphorylates) 
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pAKT to AKT), might function in dephosphorylating Jd4 which leads to tumor 
suppression that we see in PCa and increase in dephosphorylated ld4 increases PTEN 
levels which serves as a feedback loop. Overall these observations lead us to investigate 
phosphorylation of serines at position 5 on ld4 protein. 
Based on preliminary results demonstrating that ld4 dependent regulation of (JHC 
data PTEN mRNA and protein levels) of PTEN, pAKT and AKT made us to investigate 
our first aim to determine the mechanism by which Id4 regulates PTEN expression/ 
function. 
4.1.1 Methylation and Acetylation of PTEN Promoter 
At the epigenetic level, methylation and acetylation of PTEN were studied in the 
presence or absence of Jd4. We observed that there was partial methylation of PTEN 
promoter in DU145+1d4 cell line to no methylation in DU145. These results prompted us 
to check histone acetylation status of PTEN promoter in the presence ofld4. We were 
able to identify H3K.27 acetylation marks near the PTEN promoter region using 
bioinformatics approaches. Experimentally we did not see significant difference in 
acetylation of PTEN in DU145 and DUI45+1D4 cell lines (Figure 20). 
Methylation 






Figure 20. PTEN promoter methylation and acetylation: a. Showing Partial methylation of the PTEN 
Promoter in DU 145. b. Showing no significant difference comparatively in Acetylation status in DU 145. 
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4.1.2 ld4 and p53 Acetylation 
PTEN regulation occurs at the transcriptional level also. Many proteins regulate 
PTEN transcription negatively (sal-like protein 4 (SALL4), SNAIL, inhibitor of DNA 
binding I (!DI), BMII, c-JUN, ecotropic virus integration site I protein (EVIi) and 
MYC) and positively (peroxisome proliferator-activated receptor-y (PPARy), early 
growth-response protein I (EGRI), p53 and C-repeat binding factor (CBFl). 148 Human 
genomic PTEN locus contains a p53 binding element directly upstream of the PTEN 
gene, which is necessary for inducible transactivation of PTEN by p53.231 These studies 
along with data from our lab demonstrating that Id4 promotes p53 transcriptional activity 
through CBP/p300 dependent acetylation, 15 led us to investigate on whether 
transcriptional regulation of PTEN by ld4 is p53 dependent. IHC data on ld4 -/- also 
confirms that acetylated p53 expression is decreased in ld4-/- mice as compared to wild 
type and the expression of p21 a known p53 target is also decreased in Id4-/- mice 
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Figure 21. IHC on ld4-/- with p53, Acetyl p53 and p2 l. The results suggested that acetylated p53 
expression is decreased in ld4-/- mice as compared to wild type along with p2 I a known p53 target, with no 
change in total p53. Acetyl p53 is the active form ofp53 that is involved in tumor suppressor role ofp53. 
4.1.3. Binding of Acetyl p53 on PTEN Promoter 
These results prompted us to investigate whether PTEN expression is also 
regulated by acetylated p53 in the prostate. Chf P analysis on the PTEN promoter showed 
significant increase in binding of acetylated p53 on PTEN promoter in DU 145 + ld4 cell 
line compared to DU 145 cell line as shown in Figure 22. Overall these results suggested 
ld4 dependent increase in binding of acetylated p53 on PTEN promoter and Id4 regulates 
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Figure 22. ChlP Assay: Increase in the binding of Acetylated p53 to PTEN Promoter. Enrichment of 
RNA Pol 11, p53, and Ac-p53 on PTEN promoter in prostate cancer cell lines DU 145 and DU45 + ld4 cells. 
The data is expressed (mean+SEM, n�3 in triplicate) as% of input. The statistical significance between 
enrichment (indicated by letters"** *" corresponding to Pol II and Ac-p53 respectively) is based on 
comparison with DUl45 cells(*: P<0.001). 
4.2. Role of PTEN-pAKT Axis in Regulating ld4 Phosphorylation 
ld2 acts as a tumor suppressor in dephosphorylated form and tumor promoter in 
phosphorylated form in different cancers where serine 5 of SPVR region gets 
phosphorylated.26 With this observation along with using one of the Bioinformatic tool, 
NetPhosK 1.0 Server (see Figure 15), we were able to focus on possible serines in ld4 
that might get phosphorylated based on this score. Serines 5 and IO possessed highest 
score but we initially focused on serine 5 based on the previous study.26 This observation 
along with the observation that Id2 study as previously discussed, made us to study aim 
2, that is whether PTEN-pAKT axis regulates ld4 activity by phosphorylation and vice­
versa Id4 regulate AKT pathway by dephosphorylating pAKT to AKT via regulating 
PTEN. 
4.2.1 Kinase Assay: ld4 Regulates PTEN/Akt Axis 
Phosphorylation of proteins is a posttranslational modification that affects 
intracellular signaling. Functional regulation by phosphorylation has been well 
documented for many transcription factors.232 For example tumor suppressor Rb gene 
that is composed of two sets -pl I0Rb, an un- or under-phosphorylated species, and 
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pp 112- l l 4Rb, a group of overtly phosphorylated proteins is wholly unphosphorylated in 
GI, and gets phosphorylated at the beginning of S phase and remained phosphorylated 
through S phase and 02 phase of the cell cycle.233-234 2% of eukaryotic genes code for
protein kinases that are involved in catalyzing phosphorylation events.235 Conserved 
amino acid sequence SPVR, in Id proteins is a phosphorylation target by cyclin E-cdk2 
and cyclin A cdk2 kinases.26 Kinase Assay was performed to study the role ofld4 in 
phosphorylation of AKT as initial studies, show Id4 regulates pAKT. Kinase assay 
determines AKT kinase activity in the cell that is measured in terms of Glycogen 
synthase kinase 3 (OSK- 3) phosphorylation. Results from Figure 23 indicated that kinase 
levels in terms of GSK phosphorylation decreased in the presence of ld4 in DU 145 
suggesting the antitumor role ofld4. Kinase assay not only determines Id4 role in 
PTEN/AKT pathway but also can solve whether in this process ld4 gets phosphorylated 
or unphosphorylated as seen in Jd2. 
DU145+1d4 DU145 
Figure 23. Kinase Assay. Showing pAKT activity (in terms ofpGSK levels) is decreased in the presence 
ofld4. thus indicating the role ofld4 in phosphorylation that can be antitumoric. GAPDH is used as 
loading control. 
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4.2.2 Treatment with PBK Inhibitor Lead to ld4 Expression in DU145 Cells 
In the initial studies we observed Id4 upregulates and vice-versa downregulates 
pAKT, speculating the role of ld4 in PTEN/ AKT pathway in DU 145 cells. Id4 also 
reduced the levels ofphospho-GSK as seen above. To further confirm the role ofld4 in 
PTEN/AKT axis we treated DU145 cells with PI3K inhibitor (L Y294002) that inhibits 
PIP2 phosphorylation to PIP3 which further blocks AKT phosphorylation. Treatment 
with PI3K inhibitor increased PTEN expression in DU145 cells as noticed in initial 
studies). Thus this study further confirms that Id4 induces PTEN in DUl45 cells that, in 
tum, dephosphorylates AKT. Expression of ld4 after treatment with L Y294002, as seen 
in Figure 24, indicates that ld4 may be is subjected to phosphorylation even though there 
is no change in kinase levels before and after treatment with L Y294002. Further, Kinase 
levels are determined in terms of phospho-GSK as seen in Figure 25 after treatment with 
L Y294002. Id4 by regulating PTEN, can maintain AKT phosphorylation status and by 
doing so may acquire one of the phosphorylation forms. To clarify this, we performed IP 
with ld4, followed by western blot with global phosphoscrine antibody. Possible 
phosphorylation of ld4 was seen in DU 145+1d4, PC3 and MDA-MB-231, breast cancer 
cell line used as loading control for Id4 (Figure 26). To further confirm the 







Figure 24. Treatment with LY294002. Western Blot showing the expression levels of ld4 after treatment 
with LY294002 in DU 145 cell line, with a comparative increase in PTEN after treatment with L Y294002. 








Figure 25. Kinase Assay showing pAKT activity. In terms of Pgsk, levels remained almost same in 




Figure 26. ld4 Phosphorylation -IP with ID4 & Western blot with phospho serine. Phosphorylation was 
observed in DU 145+Id4, PC3 and MDA-MB-23 l(Breast cancer cell line that expresses Id4 used as a 
control). 
CHAPTER V 
DISCUSSION AND CONCLUSION 
Phosphoinositide 3-kinase (PBK)-AKT pathway modulates cell growth, 
metabolism, differentiation, migration, survival, and proliferation of a wide variety of cell 
types.236 Misregulation of this signaling pathway can cause several disorders, including 
leukemia and/or autoimmunity or alternatively immune deficiencies.237 Since the 
discovery of PTEN and its role as a phosphatase, the PIP3-Akt pathway assumes 
significance as a major cancer pathway.238 PTEN remains one of the main factors in 
modulating proteins such as AKT and p53 that are altered in cancer.90· 239 PTEN, the main 
negative regulator of PBK-Akt pathway functions as regulator of cell polarity and also as 
a switch between cell proliferation and migration, various types of cancer.238
Unlike p53, a tumor suppressor which is acutely and rapidly upregulated in 
response to oncogenic stress, PTEN expression is constitutive and essential at all times.240
PTEN is shown to be regulated by transforming growth factor� (TGF�).241 PTEN is 
upregulated transcriptionally by factors such as peroxisome proliferation-activated 
receptor A (PPARA), 141 and the early growth regulated transcription factor-l(EGRl). 142 
There is a P53 putative binding element in the promoter sequence of PTEN, 231 that 
suggests a p53 mediated cellular survival mechanism that functions through the 
activation of PTEN transcription. 
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In Id4 -/- studies, we observed focal hyperplastic regions resembling PIN like 
lesions. Many of the genes associated with PCa and their respective knockout/transgenic 
phenotypes are also recapitulated in the Id4-/- model that support the role of Id4 in PCa. 
Apart from loss ofNkx3.I as discussed in our recent study, 18 a decrease in PTEN 
specifically in the prostate, sustained androgen receptor expression, increased Myc and 
Sox9 also promote early stages prostatic intraepithelial neoplasia. 223 Our results suggest 
that the above noted genes and their regulated pathways are downstream of Id4. 
However, in spite of these complex alterations, we did not observe a significantly greater 
number of pre-neoplastic lesions in Id4-/- prostate suggesting the possibility of 
mechanisms/pathways that restrains the formation of significant pre-cancerous lesions 
and PCa. One of these pathways could involve AKT, a kinase on which many of these 
pathways converge. AKT I and AKT 2 deficiency is sufficient to reduce the incidence of 
tumors in Pten (+/-) mice,242 and Myc also cooperates with Aktl in promoting prostate 
tumorigenesis.243 Thus loss of AKT could be a key mechanism that negatively regulates 
the formation of PIN like lesions given the remarkable pro-neoplastic gene signature in 
ld4-/- mice. Loss of AKT I also leads to increased apoptosis and general growth 
retardation that affect the size of organs.244 We speculate that the smaller genital tract and 
prostate in Id4-/- could be in part due to decreased AKT expression. 
In this study, we provide significant evidence demonstrating the role of Id4 in 
PI3K -AKT pathway. At the core of the pathway is the expression of PTEN, which is 
positively regulated by Id4. Upregulation of PTEN in the presence of Id4 led to a 
decrease in levels of pAKT. p53 acetylation by Id4 and its subsequent binding to the 
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PTEN promoter appears to the underlying regulatory mechanism. We predict ld4 plays 
an important role in modulation of PTEN activity in PCa cells. If this theory with 
evidence works, it would suggest that ld4 might be used for the first time as physiological 
agent to upregulate PTEN which will intum regulate AKT pathway, thus regulating cell 
proliferation and cell division in cancerous cells. Additionally ld4 by modulating PTEN 
and regulating AKT pathway may intum get phosphorylated or dephosphorylated that 
can address one of the mechanism by which ld4 acts as a tumor suppressor in PCa. 
Although it has been reported that ld4 exerts tumor suppressive activities in several 
cancer models as presented in literature herein, it is possible that ld4 may act as tumor 
suppressor in a PTEN- p53-independent manner by regulating AKT pathway. However in 
tumors with PTEN loss, both mTORCl and other molecules upstream in the pathway 
including Pl3K and AKT PI3/AKT should be inhibited. lfwe find that ld4 act as tumor 
suppressor in the absence of PTEN, we will continue to investigate the functional role of 
ld4 and its effects on the apoptotic and/or senescence pathway in the cellular 
environment. 
PART II 
1D4 PROMOTES AR EXPRESSION AND BLOCKS TUMORIGENICITY 
OF PC3 PROSTATE CANCER CELLS 
CHAPTER VJ 
INTRODUCTION 
Deregulation of tumor suppressor genes is associated with tumorigenesis and the 
development of cancer. In PCa, ID4 is epigenetically silenced and acts as a tumor 
suppressor. In normal prostate epithelial cells, ID4 collaborates with androgen receptor 
(AR) and p53 to exert its tumor suppressor activity. 15· 17· 20 Previous studies have shown 
that ID4 promotes tumor suppressive function of AR whereas loss of 1D4 results in tumor 
promoter activity of AR. 17·19 Ectopic ID4 expression in DUl45 cells attenuates
proliferation and promotes AR expression suggesting that ID4 promotes AR expression. 
In this study, we examined the effect of ectopic expression of ID4 on highly malignant 
PCa cell PC3. Stable overexpression of ID4 in PC3 cells leads to increased apoptosis and 
decreased cell proliferation and migration. In addition, in vivo studies showed a decrease 
in tumor size and volume of!D4 overexpressing PC3 cells, in nude mice. At the 
molecular level, these changes were associated with increased androgen receptor (AR), 
p2 I, and AR dependent FKBP5 I expression. At the mechanistic level, 1D4 may regulate 
the expression or function of AR through specific but yet unknown AR co-regulators that 
may determine the final outcome of AR function. 
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7.1 AR in Prostate 
CHAPTER VII 
LITERATURE REVIEW 
The prenatal development of the prostate is dependent on androgen, particularly 
DHT. The fetal testis produces testosterone, which is reduced by Su-rcductase enzyme 
that is present in the urogenital sinus before and during prostate development. After the 
development of the prostate, androgens continue to function in promoting the survival of 
the secretory epithelia, the primary cell type thought to be transformed in prostate 
adenocarcinoma. In the normal prostate, the rate of cell death is 1-2% per day, which is 
balanced by a 1-2% rate of proliferation. The reduction of serum and prostatic DHT 
levels by castration results in a loss of 70% of the prostate secretory epithelial cells due to 
apoptosis in adult male rats, but the basal epithelia and stromal cell populations are 
relatively unaffected. AR is also expressed in the prostatic stroma, although castration 
results in the loss of stromal AR expression. The prostatic stroma therefore has the 
capacity to respond to androgen, but androgen is not required for its survival. 
In humans, the proliferation occurs predominantly in the transitional zone of the 
prostate, the region that is primarily affected in benign prostatic hypertrophy but is 
seldom the initial site of prostate carcinoma formation. Although individual cases of PCa 
have been reported in anabolic steroid users, epidemiological studies have failed to 
establish a link between elevated serum testosterone, DHT, or adrenal androgens and PCa 
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risk, suggesting that elevated testicular and adrenal androgens alone do not significantly 
promote prostate carcinogenesis. Although serum androgens alone may not promote 
prostate carcinogenesis, androgen action and the functional status of AR are important 
mediators of PCa progression. Low serum testosterone levels in men with newly 
diagnosed and untreated PCa have been found to correlate with higher AR expression, 
increased capillary vessel density within the tumor, and higher Gleason score. AR 
expression is observed in primary PCa and can be detected throughout progression in 
both hormone sensitive and hormone refractory cancers. Epigenetic silencing of AR 
expression by methylation may occur and has been observed in 8% of primary PC as. 
Another possibility for the loss of AR expression in some tumor cells is a decrease in AR 
protein stability that reduces the AR protein level to one difficult to detect 
immunohistologically.245 AR is also degraded by ubiquitin targeting to the proteasome. 
Ubiquitination of AR is promoted by AKT kinase-mediated phosphorylation of the 
receptor, suggesting that cells with increased AKT activation may have a reduced AR 
protein level. 
7.2 AR as Tumor Suppressor and Tumor Promoter 
AR may act both as a tumor suppressor and a proliferator in the prostatc.246-247
Over-expression of AR in PC3 cells results in decreased invasion in, in vivo mouse 
models whereas mice lacking the prostate epithelial AR (PEARKO) have increased 
apoptosis in epithelial luminal cells and increased proliferation in epithelial basal cells 
resulting in the expansion of CK5/CK8-positive intermediate cells. The PERKO mice 
developed larger and more invasive metastatic tumors in lymph nodes and died earlier 
than wild-type littermates.246
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AR activity and function is regulated by many co-factors and chaperones.248 In 
this context, ID4 appears to be one of the key regulators of AR function. Results suggest 
that in the presence of ID4, AR functions as a tumor suppressor whereas loss of ID4 
promotes AR to act as a tumor promoter. 17· 19·20 Identifying new or complex interactions 
between AR co-/regulators could provide some insight into possible mechanisms by 
which AR undergoes transition between a tumor suppressor vs. tumor promoter. Herc, we 
report that ID4 acts as a regulator of AR by not only inducing AR expression but 
promoting its tumor suppressor activity, leading to induction of apoptosis and inhibition 
of cell migration and growth, in more metastatic PC3 cells. 
7.3 AR Regulated Transcriptional Factor: FKBPSI 
FKBPs which belong to the family ofimmunophilins, exert important nuclear 
functions, mediated by histone chaperone activity, interaction with transcription factors, 
and modifications of chromatin structure and also play a role in cancer pathogenesis.249
FKBPs, such as FKBPSI, FKBP25, FKBP38, FKBP12, and FKBP52 indirectly associate 
with DNA and affect gene expression through interaction with transcription factors or by 
histone modification.250 In PCa, FKBPS 1 is part of a super chaperone complex that 
includes androgen receptor (AR) and androgen and plays an active role in cell 
proliferation in both the physiologic conditions of cell growth and differentiation, and in 
pre-neoplastic and neoplastic diseases and its deregulation leads to resistance to cell 
death.249· 251 Studies show that deregulated FKBPS 1 as a prime factor in the etiology of 
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androgen-dependent PCa.252 In androgen-dependent tumor cell lines, FKBP5 l 
hyperexpression increased androgen receptor transcriptional activity in the presence and 
absence of androgens; whereas, knockdown of FKBP5 l dramatically decreased androgen 
dependent gene transcription and proliferation.253 On the other hand, it has been shown 
that FKBP5 l is a more reliable marker than PSA because it is induced by AR more 
rapidly and more strongly than does PSA.254 On the basis of these studies, FKBP5 l 
serves not only as a useful target for innovative therapies that block the androgen­
receptor signaling axis in PCa but also as a AR regulated transcriptional factor. 
7.4 1D4 and AR 
In PCa cell lines it shows that Id4 protein has a different effect on the cell cycle to 
the other Id proteins. Id4, when ectopically over-expressed in PCa cell lines, induced S 
phase arrest and apoptosis and this was attributed to ld4 up-regulating the expression of 
E2A which in tum increased the levels ofp21 and p27 expression. Id4 has also been 
demonstrated to increase cyclin e levels in cdkn2a -/- astrocytes, which drives their 
proliferation. 199 And in neural precursors, Id4 protein is required for the G 1 to S phase 
transition in the cell cycle.200 All knockout ld4 mice studies revealed that ld4 plays an 
essential role in neural stem cell proliferation and differentiation,200 and normal brain 
development.211 ID4 acts as a tumor suppressor in PCa, and its loss, frequently observed 
in PCa, promotes CRPC through constitutive AR activation. 17 Id4 is regulated by 
androgens in cells that respond to androgen stimulation such as testicular sertoli cells and 
prostate epithelial cells.225 ld4 also restores androgen receptor expression and activity in 
the androgen receptor negative PCa cell line DU145. 19 
ID4, a dominant negative helix-loop-helix transcriptional regulator is highly 
expressed in normal epithelial cells of the prostate. 161· 255 In PCa, ID4 expression is
progressively lost with increasing stage of the disease, 161 due to promoter hyper­
methylation. 19· 161· 256 We have previously reported that knockdown of Inhibitor of
differentiation-4 (ID4) in PCa LNCaP cells, promoted tumorigenicity with a gene 
expression signature that resembles that of constitutively activated AR in castrated 
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mice. 17 Conversely, ectopic ID4 expression induced re-expression of AR that led to 
decreased proliferation and increased apoptosis in otherwise androgen receptor negative 
PCa cell line DU145. 19 Previous study from our lab shown in Figures 27 and 28,
determined that in DU 145 cells, ID4 functions as a tumor suppressor and when 
overexpressed in DU 145 cells, it led to expression of AR and other genes such as p2 l, 
p27 that are needed for AR to function as a tumor suppressor protein. 19 To further
elucidate the role of ID4 in PCa, we utilized more metastatic and tumorigenic PC3 cells, 














Figure 27. Androgen receptor expression analysis. A (Upper Panel) Expression of androgen receptor (AR) and E2A 
(El2/E47) bllLH transcription factor by RT-PCR. The gain of androgen receptor expression in DU 145-Id4 cells as compared to 
DU 145 cells al the transcript and protein level is evident. As controls, the parental, mock transfected DU145 cells (AR -ve) and 
LNCaP (AR +ve) cell lines were used. The expression ofbeta-actin was used as loading and RT-PCR control. B. Real time PCR 
analysis, performed on the same batch of reverse transcribed RNA used in panel A confinns the RT-PCR data. The fold change in AR 
expression is nonnali1.,ed to bcta-actin. 
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Figure 28. Gene expression changes in DU145+ld4 cell lines. (A): RT-PCR and semi-quantitative 
expression levels of cyclin dependent kinase inhibitors p27 and p21 in DU 145, DUl45-Id4 and PrEC 
(normal prostate epithelial) cells. (8) Semi-quantitative analysis ofRT-PCR results shown in (A). (C): Real 
time analysis of ld4, p53 and E-cadherin gene expression in DU 145, DU 145-CMV and DU 145-ld4 cell 
lines. The real time data is normalized to the constitutively expressed gene beta-actin. 
CHAPTER VIII 
RESULTS 
8.1 Generation of 1D4 Expressing PCa Cell Line 
Stably transfected PC3 with pCMV+l04 vector expressed nearly 2.5 fold higher 
1D4 expression (PC3+1D4) cells as compared to the control vector (PC3+CMV) 
transfected cells. The 1D4 expression in control vector transfected cells was negligible 
and was comparable to that in parental PC3 cells. Expression of 1D4 was measured by 
quantitative PCR (Figure 29A) and western blotting (Figure 298). 
8.2 Effect of1D4 on Morphology, Cell Proliferation and Migration 
A change in morphology in PC3+1D4 cells was observed (Figure 29C, Left 
panel). PC3+1D4 cells had an "epithelial like" morphology that was associated with 
increased cell-cell adhesion as compared to a mesenchymal morphology of the PC3-
CMV cells (Figure 29C, Right panel). At the molecular level, the transition towards 
"epithelial" morphology and increased cell adhesion of PC3+1D4 cells could be due an 
increase in E-cadherin expression (Figure 29D and 29E). Overexpression of 1D4 also 
attenuated proliferation of the PC3 cells. The PC3+1D4 cells had a 2 fold decrease in 
proliferation (Figure 29F), as compared to control cells. KI-67, a cellular marker for 
proliferation present during all active phases of cell cycle, was also reduced in PC3+1D4 
cells compared to control cells (Figure 29G). Next, we investigated the effect on 
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apoptosis in these cells by flow cytometry. The rate of apoptosis in PC3+ID4 cells was 
significantly higher as compared to PC3-CMV control cells (Figure 29H). Western blot 
analysis showed an increase in BAX expression, a marker associated with apoptosis in 
PC3+1D4 cells, compared to PC3-CMV cells (Figure 291). The Cyclin dependent kinase 
inhibitor p21, a well-known inhibitor of cyclin-dependent kinases acts as a key factor for 
the regulation of cell growth is upregulated by AR in PCa cell lines.257 Consistent with 
this observation, Western blot analysis showed stable 1D4 expression in PC3 cells 
resulted in upregulation of p2 l levels (Figure 291), compared to PC3 control cells. 
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Figure 29. Stable overexpression of ID4 with pCMV-1D4 in PC3 cells. Expression of ID4 was evaluated 
with real time PCR (A) and Western Blot (B). C: Morphology of the PC3-CMV and PC3+1D4 cells in 
culture. D and E: Analysis of E-cadherin by Western blot and lmmuno-cytochemistry. F: Proliferation rate 
of PC3-CMV and PC3+1D4 cells expressed as absorption at 570 nm (means± SEM, n = 3: ***, P <.00 I). 
G: Ki-67 expression by Western Blot. H: Percent of cells undergoing apoptosis by flow cytometry (***: 
P < 0.00 I). I: Western blot analysis of BAX, and p2 I. GAPDH was used as loading control. 
PC3+1D4 cells showed significantly decreased migration compared to the PC3-
CMV control cells (Figure 30A and 30B) in a transwell migration assay. Collectively, 
these results demonstrate that 1D4 expression decreases proliferation and increases 
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Figure 30. ID4 regulates migration. A. ID4 significantly inhibited migration in PC3+1D4 cells compared 
to PC3---CMV and PC3+EGF cells (positive control). Each bar represents Mean± SEM (n � 3). (*** p < 
0.001 compared to PC3-CMV). B: Representative images of PC3+EGF, PC3 CMV and PC3+1D4 cells 
after migration of cells through Trans well ( x I 0). 
8.3 1D4 Promotes AR Expression 
Real time PCR demonstrated that PC3+1D4 cells have 4 fold greater AR 
expression compared to PC3-CMV cells (Figure 3 lA). Western blot analysis further 
demonstrated greater AR protein expression in PC3+1D4 cells compared to PC3-CMV 
cells (Figure 31 C). Immuno-cytochemistry further confirmed increased expression of 
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androgen receptor in PC3+1O4 cells (Figure 31D). The AR expression in PC3+1D4 cells 
was localized primarily to the nucleus (Figure 3102) with an increase in expression and 
nuclear localization after treatment with l0nM R1881 (Figure 31D4). In contrast, AR was 
not expressed in PC3-CMV cells treated with vehicle alone but was expressed only after 
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Figure 31. ID4 regulates expression of AR. A and B. Quantitative real time RT-PCR of AR and FKBP5 I 
respectively (mean± SEM, n=3 in triplicate, normalized to GAPDH followed by fold change over PC3-
CMY cells***: P < 0.00 I). C: Western blot analysis of AR and FKBP5 I in PC3- CMV and PC3+1D4 
cells (±RI 881). GAPDH was used as loading control. D: AR immuno-cytochemistry (red). The cells were 
counterstained with DAPI (blue) to reveal the nucleus (x200). E: Enrichment of Pol II and AR, on FKBPS I 
promoter in PC3-CMV, PC3+1D4 cells. The data is expressed (mean±SEM, n=3 in triplicate) as% of input 
("a", and "b" corresponding to Pol JI, and AR respectively, p<0.001 compared with PC3 - CMV cells. F: 
The AR transcriptional activity as determined by PSA AR response element driven luciferase reported 
plasmid. The data is normalized to Renilla luciferase. The mutant ARR3 luciferase reporter plasmid was 
used as a negative control (mean ± SEM *** : P < 0.001 as compared to respective ARR3 luciferase, a: 
p<0.001 as compared to PSA luciferase activity in PC3-CMV, c: p<O.0 I as compared to PC3+1D4, n=3). 
FKBP5 l, a well-established AR regulated gene was used to assess the 
transcriptional activity of AR. 1D4 induced FKBP5 l expression at both mRNA and 
protein levels in PC3+1D4 cells (Figure 31 B and 31 C). Androgen-dependent transcription 
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of the FKBP5 I is conferred through a non-canonical androgen response element (ARE) 
element within an intron.254 Chromatin immuno-precipitation analysis using androgen 
receptor antibody revealed that binding to FKBP5 I promoter is significantly increased 
(P < 0.00 I) in PC3+1D4 cells compared to PC3 control cells (Figure 31 E). These results 
suggest that ID4 promotes binding of AR to FKBPS I promoter. 
In order to further assess the transcriptional activity of AR, the activity of 
luciferase driven by the PSA promoter was performed. The relative PSA luciferase 
activity increased significantly in PC3+ID4 cells as compared to PC3-CMV cells 
(Figure 31 F), which is consistent with the increased expression of AR in these cell 
lines. The mutant ARR3 luciferase plasmid (mt-ARR3 RE) used as a negative control, 
did not result in significant luciferase activity. (Firefly PSA is nomialized to Renilla 
empty vector). 
8.4 1D4 Results in Decreased Tumor Growth in Vivo 
The influence of 1D4 on tumor formation by PC3 was examined by measuring 
the size and weight of the tumors. PC3-CMV control cell tumors in nude mice were 
observed within I week of injection (Figure 32A and 328). In contrast, PC3+1D4 cells 
formed tumors after a latency period of approximately 3 weeks, which led to a 
significant decrease in tumor growth. At the end of the experiments (6 weeks), the 
tumors were excised and volume and weights were measured (Figure 32C and 32D). 
The PC3+1D4 cells formed smaller tumors compared to PC3 control cells. 
Collectively, these results indicate that overexpression of ID4 decreases tumor growth 















Figure 32. Stable overexpression of 104 in PC3 cells suppresses tumor growth in vivo. Male and nude 
mice were injected with PC3-CMV and PC3+1D4 cells and evaluated for tumor volumes and tumor 
weights. A: Representative xenograft images with numbers of mice with similar tumor (n) are shown. B: 
Volumes of the tumors were measured weekly (expressed as mm3, means±SEM, n = 3/group, ***, p < 
.001, and *p<0.0 1 between PC3-CMV and PC3+1D4). The mice were sacrificed at 6 weeks. C, D: Relative 
volumes and weights (means±SEM, n = 3) of the tumors after excision(•••, P < .00 I, between PC3- CMV 
and PC3+1D4 tumors). E: TUN EL assay demonstrated increased apoptosis in in PC3+1D4 mice xenograft 
(Brown staining) as compared to the PC3-CMV cells. The TUN EL positive cells were counted in five 
fields (at 400x) on three different tissue samples. 
Xenografts derived from PC3+ID4 cells showed significantly more apoptotic 
cells compared to xenografts from PC3-CMV cells, confirming a role for 1D4 in 
promoting apoptosis. 15 The average number of TUN EL positive cells in PC3+ID4 
xenograft tissue is significantly higher compared to PC3 control xenograft tissue 
(Figure 32E). 
CHAPTER IX 
DISCUSSION AND CONCLUSION 
The role of!D4 in cancer has not been clarified; however, studies support both a 
pro-tumor and anti-tumor activity of ID4. ID4 promoter methylation demonstrates its role 
as a potential tumor suppressor and oncogene in a context dependent manner. We have 
shown that ID4 expression is decreased due to promoter methylation in PCa.220
Epigenetic silencing of ID4 promoter tend to support its tumor suppressor role in PCa. 
In PCa cell lines, ID4 promotes cell cycle arrest and apoptosis, by up-regulating the 
expression of p21 and p27. 19 In the present study also, ID4 decreases migration and cell 
proliferation of PC3 cells, which is associated with an increase in p2 l ,  a regulator of cell 
cycle progression at GI and S phase and with a significant decrease in Ki 67, a marker of 
proliferation. 258 PC3+ID4 cells showed increased apoptosis and decreased cell migration 
compared to control cells. Most importantly we show an up-regulation of a E-cadherin a 
well-established tumor suppressor and inhibitor of epithelial to mesenchymal transition, 259
by ID4. ID4 may directly regulate E-cadherin expression by neutralizing basic helix loop 
helix E2A proteins that negatively regulate E-cadherin gene expression through E-Box 
response elements.260 Alternatively, increased AR expression in PC3+ID4 cells may itself 
promote e-cadherin expression.261
Collectively, these results demonstrated that ID4 expression induces a change in 
cell morphology AR plays a tumor suppressor role in normal cells and functions as tumor 
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promoter in PCa cells.248- 262-264 Various studies have shown that AR mRNA and protein
expression are low but detectable in PC-3 cells.265-266 Studies with treatment of PC3,
DU145, and LAPC4 cells with RI881 and DHT showed increased AR levels only in PC3 
cells, with no effect in DU 145 and a negative effect in LAPC4 cells suggesting that PC3 
retained the necessary cofactors to engage AR as a tumor suppressor.267 Addition of 
functional AR in PC3 cells resulted in decreased invasion in bone lesion assay and in 
mouse models.246 Induction of AR expression and activity in PC3 cells indeed results in 
growth suppression, 248· 257· 261· 268 which is probably mediated by co-regulators that enable 
AR' s normal tumor suppressor function. 
Our results demonstrate that ID4 may activate the tumor suppressor activity of 
AR by inducing expression of target genes P2 I and FKBPS 1, and by decreasing 
expression ofKI67, in PC3 cells. At the mechanistic level, ID4 may regulate the 
expression or function of specific but yet unknown AR co-regulators that may determine 
the final outcome of AR function. 
In conclusion, ID4 may restore AR expression and activity in PC3 cells, which 
may contribute to the tumor suppressor function of 1D4. Therefore, AR-dependent and -
independent pathways may contribute to the tumor suppressor function of ID4. 
Identification of the factors that mediate these effects in these PCa cells will improve our 
understanding of mechanisms that contribute to tumor invasion and therapeutic resistance 
associated with androgen deprivation therapy. 
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